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Preface
This technical memorandum is a compilation of the results of a 4-day head-down bed rest (HDBR) study. This study was
designed to investigate the effects of 4 days of HDBR alone or with 2 or 4 hours of standing or walking intermittently
during each day of HDBR on orthostatic tolerance, maintenance of working capacity (peak oxygen uptake), calcium
excretion, and endocrine and fluid and electrolyte responses. The following investigators participated: A. C. Ertl, Ph.D.,
C. E. Wade, Ph.D., L. Keil, Ph.D., J. E. Greenleaf, Ph.D., and D. O'Hara, R.N., NASA Ames Research Center, Moffett
Field, CA 94035-1000. In addition, M. R. Duvoisin, Ph.D., and J. L. Stinn, Ph.D., Biomedical Operations and Research
Office, NASA Kennedy Space Center, FL 32899, were instrumental in developing the software for the monitoring and
recording of continuous cardiovascular data during the orthostatic tests and St. J. Maloney and V. Reyna for data
analyses and compilation of this document. Portions of this report were funded by NASA Ames Research Center
Consortium Agreement #NCA2-629.
Joan Vernikos, Ph.D.
Chief (Acting)
Life Science Division
NASA Ames Research Center
Moffett Field, California
David A. Ludwig, Ph.D.
Associate Professor of
Mathematics and Statistics
University of North Carolina
Greensboro, North Carolina
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ANCOVA
ANOVA
ANP
APA
AVP
BP
bpm
BR
BV
C
Ca
DBP
E
F
G
Gz
GFR
Hct
HDBR
HDL
analysis of covariance
analysis of variance
atrial natriuretic peptide
alkaline picric acid
arginine vasopressin
blood pressure
beats per minute
bed rest
blood volume
ambulatory control
calcium
diastolic blood pressure
epinephrine
fainter during tilt test
gravity
gravity in head-to-toe vector
glomerular filtration rate
hematocrit
head-down bed rest
high density lipoprotein
HR heart rate
HRF Human Research Facility
ISE ion specific electrode
K potassium
LBNP lower body negative pressure
LDL low density lipoprotein
MAP mean arterial pressure
Na sodium
NE norepinephrine
NF non-fainter during tilt test
P probability value
PRA plasma renin activity
PV plasma volume
RIA radioimmunoassay
S standing condition (e.g., $4, standing
for 4 hours)
SBP systolic blood pressure
SD standard deviation
SE standard error
VO2pea k peak oxygen consumption
W walking condition (e.g., W4, walking
for 4 hours)
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Intermittent Gravity: How Much, How Often, How Long?
JOAN VERNIKOS AND DAVID A. LUDWIG*
Ames Research Center
Summary
Continuous exposure to gravity may not be necessary to
prevent the deconditioning effects of microgravity. It is
not known, however, what the minimum gravity (G)
exposure requirements are, whether they vary for different
physiological systems, or whether passive Gz (gravity in
the head-to-toe vector) or activity in a G field is more
effective in preventing deconditioning. It is also not
known what the optimal characteristics of the G stimulus
should be in terms of amplitude, duration, and frequency.
To begin to address these questions, we conducted a 4-day
-6 ° head-down bed rest (HDBR) study. Nine males (aged
30-50 yr) were subjected, over a period of seven months,
to four different + l Gz exposure protocols (periodic stand-
ing or controlled walking each for a total of 2 or 4 hr/day
in individual 15-rain doses), plus a control (0 Gz) of con-
tinuous HDBR.
The study consisted of one ambulatory control day, 4 full
days of-6 ° HDBR, and a recovery day when subjects
were released at the end of HDBR after completion of
tests. A battery of tests was selected and standardized in
order to evaluate the known early responses to HDBR.
Dependent variables of interest included orthostatic toler-
ance (30 rain at 60 ° head-up tilt) and hemody.namics dur-
ing head-up tilt, peak oxygen consumption (VO2pea k)
plasma volume (PV), and urinary calcium (Ca).
The results were as follows: (1) 4 hr standing completely
prevented and 2 hr walking partially prevented post-
HDBR orthostatic intolerance. Walking at 3 mi/hr for
4 hr/day provided no additional benefit. (2) Intermittent
walking attenuated, but did not prevent, the decrease in
VO2pea k. (3) Both 4 hr conditions showed less PV loss
by the end of HDBR; both 2 hr conditions were without
effect. (4) Both 2 and 4 hr walking essentially prevented
urinary Ca excretion and were more effective than stand-
ing. It is concluded that different physiological systems
benefit differentially from passive +1 Gz or activity in
+1 Gz, and the intensity of the stimulus may be an
important contributing factor.
Introduction
All terrestrial living systems, including humans, have
evolved over millions of years in the continuous presence
of Earth's gravitational force, gradually developing,
adapting, and migrating from sea to land. It is therefore
not too surprising that animals and humans physiologi-
cally decondition very rapidly in microgravity, suggesting
that chronic exposure to gravity (G) is important in main-
taining a gravity-adapted state. Whether this chronic
exposure must be continuous or can take the form of peri-
odic "vaccinations" has been the subject of a few studies
conducted mostly in the sixties and of much debate and
speculation over the ensuing years. In the meantime, the
search in the last 30 years for effective countermeasures
to the effects of spaceflight has met with limited success.
Concern is growing, especially as longer duration mis-
sions are being planned, that either comprehensive coun-
termeasures will not be developed in time or that effective
countermeasure procedures will be so time consuming
and cumbersome that it would be unrealistic to expect
crews to devote 2-4 hr/day, as some Russian crews have
done (Garshnek et al., 1989), in order to maintain ade-
quate health, fitness, and productivity.
Although Soviet cosmonauts have been in space for as
long as a year and have performed an extensive and inten-
sive exercise and lower body negative pressure (LBNP)
countermeasure program, they cannot walk unassisted for
at least 48 hr after landing. They have also not been
required to maintain or restore skilled physical perfor-
mance in order to land their spacecraft as U.S. astronauts
must, be immediately able to egress in an emergency, or
perform adequately and consistently on landing in another
gravitational field such as Mars. It appears, then, that
exposure to some effective G level is probably essential to
restore vascular hydrostatic pressures, enhance the effec-
tiveness of exercise and activity on muscular strength and
endurance, aerobic work capacity, and bone integrity and
strength, and provide afferent input to maintain integrity
of neural regulatory functions.
*University of North Carolina.
Head-downbedrest(HDBR)andhorizontalbedrest,toa
lesserextent,asgroundsimulationanaloguesofmicro-
gravity,havebeenusedextensivelytoinducemostof the
physiologicaleffectsalsoobservedduringdeconditioning
inmicrogravity.Thisindicatesthatatleastthreeaspects
ofaGconditionareinvolvedinmaintainingnormal
healthandfitness:thepulloftheGforceintheGz(head-
to-toe)direction,exertionagainsttheGforce,andthe
elementof chan_eprovidedbyposturalndother
movement/orientationcuesonlypossibleinagravitational
field.
Normal,ambulatorypeoplespendapproximately8hr/day
sleeping(horizontally)andt6hr/dayintheuprightsitting
orambulatorymode.Whetherallof the16hr/dayat
+1Gzareneededtomaintainoverallnormalhealthand
fitnessisnotknown.Theresultsofclassic,thoughnot
definitive,studies(becauseofthesmallnumberofsub-
jectsused)havecomefrombedrest(BR)researchstudies
conductedattheLankenauHospitalinPhiladelphiainthe
1960s.Thesestudiesshowthat:
(a)Eighthoursdailyofquietsittingplus16hr/dayof
horizontalBRresultedinonlyminordecreasesinaerobic
capacity(maximaloxygenuptake);tilt tolerancewas
maintainedin3of 4subjects(Birkheadetal.,1964a).
(b)Cyclelegexercisefor2-4hr/dayinthesupine
positionfor i8dayswasineffectiveinreducingtilt intol-
eranceorhypercalciuria.Quietstandingfor3hr/daywith
21hr/dayof horizontalBRdecreasedtilt intolerancein3
of5subjectsanddecreasedurinarycalcium(Ca)excre-
tionin4of5subjects.Applicationof intermittentLBNP
inonesubjectattenuateddevelopmentof ilt intolerance
butincreasedurinaryCaexcretion(Birkheadetal.,1966).
(c)Onehourdailyofsupineorsittinglegexerciseat
600kpm/minfor24--42daysmaintainedaerobiccapacity,
butdidnotpreventtilt intoleranceorincreasedurinaryCa
lossinsubjects(Birkheadetal.,1963;1964b).
Rodahletal.(1967)summarizedthefindingsfrom -
these Lankenau experiments: .....
(a) Supine leg cycle exercise training for 2-4 hr/day
during BR
I. may maintain muscular strength and aerobic
capacity.
2. has no effect on urinary Ca loss.
3. has no effect on tilt intolerance.
(b) Quiet sitting for 8 hr/day during BR
1. has minimal effect on maintenance of muscu-
lar strength and aerobic capacity.
2. has no effect on urinary Ca loss.
3. reduces tilt intolerance.
(c) Quiet standing for 3 hr/day during BR
1. (muscular strength or aerobic capacity was not
measured).
2. reduces increased urinary Ca excretion to
ambulatory levels.
3. reduces tilt intolerance.
More recent evidence indicates that exposure to three
20-min sessions of LBNP (at-35 mmHg)daily virtually
eliminates orthostatic (tilt) intolerance after 30 days of
-6 ° HDBR (Guell, 1990). Kakurin et al. (1978) reported
that an exercise protocol, performed for 58-67 min/day,
consisting of leg cycling, rowing, inertial-impact loading
on the legs, and breathing exercises, maintained the
muscular strength and aerobic capacity of six men during
49 days of-4° HDBR. In addition, we have found that,
after 30 days of-6" HDBR, high intensity and short
duration aerobic exercise (leg cycle ergometry at 40%
max) for 1 hr/day maintains aerobic capacity, and high
intensity, intermittent, short duration isokinetic leg
exercise maintains strength and endurance (Greenleaf
et al., 1989; 1994). Whereas it appears possible to
maintain aerobic capacity, muscle strength, and endurance
with a variety of supine exercise procedures, some form
of orthostatic stimulus seems to be necessary to prevent
orthostatic intolerance. The magnitude and duration of
such a stimulus, however, are unknown.
The most eirfective time of day to expose subjects to a
+l Gz stimulus is also important. During the night hours
many physiological systems are unresponsive. Diuresis,
natriuresis, and calciuresis, for example, do not occur in
response to immersion or BR (Shiraki et al., 1986). This
blunting of responses is independent of sleep or posture
and appears to be a function of the circadian trough. How
pervasive this nocturnal blunting to gravitational and
other stimuli is across physiological systems has not .......
received much attention. Nevertheless, it would appear
that there is an optimal lime in the diurnal cycle when the
effectiveness of Gz stimuli are at their greatest. This opti-
mal time does not appear to be during the circadian nadir
or the nocturnal part of the cycle. It could therefore be
inferred that exposure to a Gz force by centrifugation
during sleep, as has been proposed by some (Cardus et al.,
1990), would be of no substantial benefit.
Whether it is passive exposure to +l Gz or the activity we
carry out normally in +i Gz that is t-he-Optimum stimulus
in health maintenance is another question. It has been
proposed (Whalen et al., 1988; Whalen, 1993) that, for
maintenance of bone strength, it is the activity we conduct
in a G field that is most effective. Whalen (1993) has
proposedthattheapparentbonelossifi_a_eflightissec-
ondarytothereductioni gravitationalforcesonthe
skeleton.Thisimpliesthatexerciser gimensthatare
selectedascountermeasuresmu t,inconcertwiththe
Gforce,replaceabsentmechanicalstimuliandstresses.
PeriodichypergravityexposuresduringBRhavebeen
usedinafewstudies(Murrayetal.,1965;White,1965;
Nybergetal.,1966;Piemmeetal.,1966;DowelletaI.,
1968;Kotovskaya et al., 1977; Grigor'yev and
Shulzhenko, 1979; Shulzhenko et al., 1979; Shulzhenko
and Vil-Viliams, 1992). These studies have focused pri-
marily on preventing post-bedrest or post-dry immersion
orthostatic intolerance by exposing subjects 2-3 times a
day for short periods of time to gravity levels up to +2 Gz.
Some of these studies have suggested that such intermit-
tent hypergravity exposures also induce fluid and sodium
(Na) retention and prevent changes in plasma volume
(PV). The fundamental flaw in these studies is that they
have not been comprehensive, and tests and measure-
ments vary, so that comparisons across regimens and
across physiological systems are near impossible.
Exposure of animals to continuous gravity inflight pro-
vided by an onboard short radius centrifuge on the
Cosmos-782 and Cosmos-936 Biosatellites indicated that
this exposure protected animals from the physiological
responses to spaceflight. In ground studies, using a 2 m
radius centrifuge, Shulzhenko and ViI-Viliams (1992)
exposed human subjects to periods of 40-60 min time
blocks of continuous gravity during 3-day or 28-day dry
immersions; exposure was 2-3 times a day to 1.3, 1.6, and
1.9 G either alone or with exercise or salt loading. The
beneficial effects of these exposures were very encourag-
ing. More studies are needed, but must be approached in a
systematic fashion so that specific requirements for the
most effective periodic centrifugation protocol may be
developed.
Many questions remain unanswered regarding mainte-
nance of health and fitness in spaceflight: What is the '
minimum exposure per 24 hr of +! Gz? Does exposure
have to be presented in a block of time or in divided
doses? Is it the total duration of exposure per 24 hr or the
number of bouts that is the crucial variable? What is the
most effective time of day to expose subjects? Is it passive
exposure to +1 Gz or the activity we carry out normally in
+1 Gz that is the optimum stimulus in health mainte-
nance? Does increasing the intensity of the +G z stimulus
reduce the time of exposure needed (i.e., does hypergrav-
ity increase the efficacy of +Gz exposure)? Do all physio-
logical systems respond to gravitational treatment in a
similar way? What are the side effects of short arm cen-
trifugation? Can you stress the body by providing
o ' a '_ _ _
'wei=htbearm,_ by other means such as LBNP (Hargens
et al., !991; 1992)?
In order to address systematically the many questions that
must be answered so that artificial G requirements for pro-
longed missions may be determined, it was important to
develop the simplest ground simulation model possible
whose cost would not be prohibitive and that: 1) would
give reliable, measurable, and consistent changes within
the briefest period of time; 2) could be repeated fre-
quently, preferably in the same individuals; and, 3) would
be based on an experimental design that could be random-
ized to enable relatively easy screening of various permu-
tations of G stimulus presentation. It was also important to
select the most sensitive tests available and standardize
them in order to assess the extent of the deconditioning
effects.
The value of-6 ° HDBR as a ground simulation analog of
the effects of microgravity has been well documented
(Grigor'yev et al., 1986; Convertino, 1994). Although we
and others (Dailman et al., 1984; Baisch et al., 1992;
Vernikos et al., 1993) have conducted numerous HDBR
studies of 7 days or longer, the artificial gravity working
group that met at NASA Ames Research Center (Artificial
Gravity Workshop, NASA Ames Research Center,
Galileo Room, April i i-i 3, I989) indicated that 3 or
4 days of HDBR could serve as a reliable model for the
rapid screening of preventive or therapeutic treatments, in
large part because of the sufficiently large, consistent, and
reproducible physiological responses induced during this
time. Orthostatic intolerance becomes apparent within a
few hours of-6 ° HDBR (Loeligen et al., 1984; Butler
et al., 1991), and, although PV is somewhat reduced by
24 hr, reduction is essentially maximal by 3 days
(Dallman et al., 1984; Heer et al., 1992). Diuresis and
natriuresis occur mostly within the first 48 hr (Heer et al.,
1992; Vernikos et al., 1993). Maximal oxygen
consumption changes have also been reported evident
within 48 hr of HDBR (Nixon et al., 1979). We therefore
selected 4 days of HDBR as an appropriate time frame to
acquire significant early adaptive responses and screen
various dose, time, and frequency permutations of the +Gz
stimulus. A 4-day HDBR study also had the advantage of
being both practical and cost effective as it required,
including control periods before and after HDBR, only a
week to complete.
Methods
Subjects
Nine healthy, nonsmoking, normotensive men (paid
volunteers), with a mean (SD) age of 37.9 (4.5) yr, a mean
heightof 181.7(5.1)cm,andameanweightof 84.4
(7.8)kg,gavewrittenconsenttoparticipateinthisstudy.
Participationwascontingentonapositivemedical
screeningthatconsistedof adetailedmedicalhistoryand
aphysicalexamination.Subjectswererecruitedfromthe
SanFranciscoBayAreaandwereofaverage,fitnessfor
theirage[meanpeakoxygenconsumption(VO2peak) =
32.1ml/kg/min].Priortotestingandsubjectrecruitment,
thestudyprotocolwasapprovedbytheNASAAmes
HumanResearchExperimentsReviewBoard.Subjects
werethoroughlybriefedonallaspectsoftheexperimental
.protocolbeforeconsentingtoparticipate.Oneofthenine
subjectswithdrewfromthestudyanddidnotparticipate
inthe2hrwalkingandstandingconditions.TableI
showsthesubjects'controltest data and body weights
over the seven months of testing.
Treatments and Experimental Protocol
Each of the nine subjects was tested across five treatment
conditions to evaluate the effects of periodic +1 Gz grav-
ity during 4 days of continuous -6 ° HDBR (each subject
received each treatment during five 4-day HDBR expo-
sures). The order in which the subjects received the treat-
ments was counterbalanced as much as possible but was
restricted due to the size and availability of the Human
Research Facility (HRF) at NASA Ames Research Center•
The treatments, as summarized in table 2, included: 1) no
intervention (0 Gz condition); 2) 4 hr of intermittent
standing per day; 3) 4 hr of intermittent walking per day;
4) 2 hr of intermittent standing per day; 5) 2 hr of inter-
mittent walking per day. The 4-hr treatments were con-
ducted in 15-min bouts each hour for 16 hr. The 2-hr
treatments were also conducted in 15-rain bouts but over
an 8 hr period• Standing was done quietly without support
while walking was at 3 mph on a level treadmill. Mini-
mum recovery time between treatments was one month•
In addition, each subject was tested both pre- and post-
HDBR across all conditions• Thus the experimental layout
can be viewed as a self matched (paired) experiment with
multiple controls (five pre-HDBR control measurements).
Experimental Conditions
Admission of subjects was staggered so that three subjects
were admitted daily to the HRF and released six days
later• Subjects were supervised 24 hr/day while in the
HRF to assure that they adhered to the bed rest regimen•
Transportation to and from VO2pea k and tilt test rooms
was in horizontal or -6o head-down position as appropri-
ate; showering was done in horizontal position and excre-
tory functions in -6 ° head-down position. During -6 °
HDBR, subjects were allowed one pillow. To facilitate
eating, a subject was allowed to raise his head and rest it
Table 1. Control data from tests on the same subjects during their five visits before each HDBR exposure.
N = number of subjects per group. Data are shown as mean + standard error. Tilt tolerance is the percentage of
subjects completing a 30-min 60 ° head-up tilt test
N=9 N=8 N=9 N=8 N=9
Body weight (kg) 82.72 + 2.58 84.21 + 3.44 83.49 + 2•71 84.88 _+3.30 83.50 + 2.50
Tilt tolerance 75% (6 of 8) 100% (8 of 8) 100% (9 of 9) 75% (6 of 8) 77.8% (7 of 9)
Peak _'O 2 (L/min) 2.66+0.15 2.64+0.15 2.70+0.13 2.66+0.18 2.70+0.15
PV (ml) 2685.8 _+ 169.2 2438.4 + 103.4 2607.4 + 150.8 2390•7 + 114.4 2987.6 + 289.2
Urinar), Ca/m_/24 hr ) 135.4+22.8 201.0+23.5 177.6+28.2 212.5+ 17.7 199.3+21.3
Table 2. Five treatment conditions
1. Four days of HDBR (no intervention), zero G simu-
lation condition (OG).
2. Four days of HDBR with 4 hours of intermittent
standing per day (1GS4).
3. Four days of HDBR with 4 hours of intermittent
walking per day (IGW4).
4. Four days of HDBR with 2 hours of intermittent
standing per (IGS2).
5. Four days of HDBR with 2 hours of intermittent
walkin_ per day / 1GW2).
in his hand as long as the upper part of his arm was resting
flat against the mattress• Smoking, caffeine containing
drinks, and medications (including vitamins) were not
allowed during the study. Lights were on from 0700 hr to
2300 hr for all subjects except those standing at 2315 hr
and walking at 2330 hr.
All subjects were maintained throughout the study on a
standard diet of 2500-2800 Kcal/day including 190 mEq
Na (+20) and 90 mEq potassium (K) (+10). Subjects were
required to drink a minimum of one liter/day of fluids
which included fluids from their food trays; there was no
upper limit on the amount of fluids allowed• Subjects
were required to keep accurate food and fluid intake
recordsduringthestudyincludingrecordsoftheamount
ofsodiumconsumed.
ExperimentalProcedures
In the two week period preceding each HDBR exposure,
subjects came on an outsubject basis to establish peak
oxygen consumption. Upon admission to the facility for
each HDBR exposure, an admission physical was done
which included measurement of height, weight, and vital
signs (oral temperature, heart rate, respiration, and blood
pressure). Vital signs were taken each day during the
HDBR exposure at 0700 and 1900 hr; weight and vital
signs were again determined following the VO2pea k test
on the recovery day prior to release.
On the day after admission, there was one ambulatory
control day when early-morning fasting PV and tilt toler-
ance were determined. On the following day, after
awakening, getting up, having a standardized light break-
fast and generally being ambulatory for 2 hr, subjects
began the HDBR period. Treatments started 1 hr after
beginning HDBR. Plasma volume and tilt tolerance were
again determined on day 4 of HDBR. At the end of this
tilt test, subjects, without ever ambulating, were placed
back in the -6 ° head-down position and returned to their
beds. Subjects following walking or standing treatments
resumed treatment the hour following the tilt test, thus
missing only the treatment (eplaced by the 30-min tilt test.
Subjects remained in the -60 head-down position until the
next day (the recovery day) when a VO2pea k test was
again performed using a supine bicycle ergometer.
Following completion of this last test, subjects were
allowed to ambulate and were then released.
Blood Samples
Blood samples (supine) were taken on the ambulatory
control day and on HDBR day 4 for PV determination and
for analysis of electrolytes and fluid regulating hormones.
In addition, a blood sample was taken 4 hr after beginning
HDBR and also analyzed for various fluid regulating
hormone changes as compared to a supine control blood
sample taken after lying quietly supine for 45 min on the
ambulatory control day.
Blood samples were collected using the Becton Dickinson
Vacutainer system, as appropriate, into test tubes contain-
ing heparin, EDTA, or no anticoagulant. The use of anti-
coagulants had no effect on subsequent analyses. The
tubes were kept in crushed ice and then centrifuged at
4° C for 20 min at 2500 rpm. Plasma or serum were
removed, allocated into individual tubes for each assay,
and immediately frozen for later analysis.
Urine Samples:
Volumes and times of void-by-void specimens were
recorded daily. Urine pools (24-hr) were collected
throughout each study for the determination of fluid and
electrolyte balance. Aliquots from each pool were frozen
and stored for later analysis.
Tilt Tolerance Test
Orthostatic tolerance testing was performed pre-bed rest
on the ambulatory control day, after subjects had been
lying quietly in the supine position (horizontal) for 45 rain
prior to the test. Testing was performed again on HDBR
day 4. Testing both times was performed on a NASA
developed tilt table. On the ambulatory control day, sub-
jects were transported by gurney to the tilt room in hori-
zontal position; on HDBR day 4, transportation was by
gurney with subjects in -60 head-down tilt position. In the
tilt room, subjects slid over onto the tilt table (horizontal
on ambulatory control day; -60 head-down on HDBR
day 4) and positioned themselves in the center of the table
with their feet just touching the table foot rest. A folded
towel was placed under the heels for better positioning of
the feet during tilt. A wide band, secured on both sides of
the table, was placed loosely across the waist to make the
subject feel more secure. After a 5-rain pre-tilt control
period, subjects were tilted within 10-15 sec to 60 ° head-
up for 30 min or until signs and symptoms of pre-syncope
(e.g., nausea, dizziness, sweating, lightheadedness, and
tunnel vision) occurred. Subjects were then immediately
returned to a horizontal (ambulatory control day) or -60
head-down (HDBR day 4) position for a recovery period
of at least 10 min. An Ohmeda 2300 (Ohmeda, BOC
Group Inc., Englewood, Colo.) Finapres TM blood pressure
(BP) monitor was used to monitor BP and heart rate (HR)
continuously during the test (5-rain pre-tilt control period,
tilt, post-tilt recovery period). An arm rest, attached to the
tilt table, was used to keep the subject's hand at heart
level at all times to ensure the collection of consistent and
reliable data. Pre- and post-tilt manual blood pressure
readings were also taken and recorded. Upon completion
of the test, subjects were transported back to their beds by
gurney (in horizontal position on ambulatory control day;
in -60 head-down tilt position on HDRB day 4). A medi-
cal monitor was in attendance at all times during the tests.
The Finapres fingercuff BP monitoring device used to
provide beat-by-beat measurement of peripheral BP mea-
sures BP using a small finger cuff that contains a photo-
plethysmographic volume transducer and an inflatable air
bladder. The cuff is connected to a fast-response servo
control system that instantaneously regulates the pressure
applied to the finger through the bladder and, thus, the
pressure applied to the walls of the arteries. As BP
increases,thearterialwallexpands,increasingthevolume
ofthefinger.Thisvolumedifferentialismeasuredbythe
plethysmographictransducer•TheFinapresmonitor
respondstotheincreasingvolumebyincreasingcuffpres-
sureuntiltheoriginalarterialsizeandbloodvolume(BV)
areagainreached.Theexternalpressurecontinuously
adjustedbythecuffcloselyfollowstheintra-arterialpres-
surewithinthefinger,allowingmeasurementofthe
externalpressureitselfasafunctionofthearterialBP.
Peak Oxygen Consumption Test
Prior to and following 4 days of--6 ° HDBR, VO2pea k
was determined using indirect calorimetry during supine
leg cycling ergometry. During an initial visiL subjects
were familiarized with the exercise testing equipment and
completed an incremental submaximal test. In the two
week period preceding the first HDBR exposure, a
VO2pea k test was administered. Several days later, and
before beginning HDBR, subjects completed a second
VO2pea k test to verify results of the first test. In the two
week period preceding the four subsequent _BR expo-
sures, all subjects came again on an outsubject basis to
establish peak oxygen consumption• Post-HDBR
"q'O2_ea k tests were administered on the recovery day of
all H_BR exposures. For the post-HDBR tests on the
recovery day, subjects were transported by gumey :
between the HRF and the test I:oom (before "and after
completion of the tests) in -6 ° head-down tilt position•
Subjects were horizontal during the administration of all
VO2pea k tests.
The term "QO2pea k is used rather than maximal oxy-
gen consumption ('QO 2 max) since a plateau or decrease
in oxygen consumption with an increase in load was not a
criterion for measurement. VO2pea k is defined as the
highest minute oxygen consumptzon measured during
incremental loads on the ergometer.
The protocol for VO2pea k consisted of a 5-min
warmup at 400 kg-m.min -1 which was followed by
three 2-rain incremental loads of 200 kg-m.min -1
estimated to elicit VO2pea k. If the subject was able to
complete the third incremental load, an additional increase
of 200 kg-m.min -I was given. The subjec{s _xer6ised
to volitional fatigue, or the test was terminated if the
subject was unable to maintain a pedaling frequency
above 50 rpm• After completion of the test, resistance was
reduced so that the subject could recover comfortably.
Hand grips and shoulder braces were used for stabilization
during the test.
The three loads used to reach the peak load were esti-
mated from the results of the submaximai test. In the first
VO2pea k test, the three peak loads were set to achieve
exhaustion with the third load (within 5-6 min). If the
subjects were not able to exercise for a least 1 rain at the
peak load, or required a fourth load to reach exhaustion,
the peak loads were adjusted.
Reported results are submaximal HR response to
the initial 5-rain warmup prior to the peak protocol
(400 kg-m.min -I), the average "_O2 of the highest four
15-see values obtained during the peak power output, and
the maximal HR achieved during the test.
Exercise testing was performed on a Quinton model 846T
imaging/Ergometer "Fable (Quinton Instruments, Seattle,
Wash.)• The metabolic gas collection system utilized an
on-line data acquisition system. Subjectsbreathed through
a low-resistance, high flow Rudolph valve. Inspired gas
volumes were measured using a Pneumoscan S-301
spirometer (Vacumed, Ventura, Calif.)• Oxygen and
carbon dioxide concentrations were measured on Ametek
Applied Electrochemistry (Pittsburg, PA) S-3AI and
CD-3A analyzers respectively. Analog data was
converted to digital by Vista model 17002 system and
software (Vacumed, Ventura, Calif.) and fed to an
IBM PC AT for calculation. Heart rate data was collected
on a Hewlett Packard cardiotachometer model 78905A
and ECG module model 78203C (Hewlett Packard,
Medical Products Group, Waltham, Mass.).
Plasma Volume
Plasma volume was measured using a modified Evans
blue dye dilution method (Greenleaf et al., 1979;
Greenleaf and Hinghofer-Szalkay, 1985). The procedure
was performed on each subject on the ambulatory con!fol
day and again on HDB-R day 4 after subjects were awak-
ened at 0700 hr and before they were served breakfast. A
Becton Dickinson Vacutainer Blood Collection Set with a
21-gauge needle, attached to a 3-way stopcock, was used
to obtain blood samples. A pre-injection blood sample
was drawn• The pre-weighed Evans blue dye solution
(2.5 m_/lbject) in-the-syringe was ]njected and a Second
blood sample was d_awn 10m_niaterJ_e empty Syr_e
used to inject the Evans blue was saved for weighing in
order to calculate the amount of Evans blue dye actually
used for eacla PV test_ The IV line was kept paten(witffa
slow drip of sterile 5% dextrose solution. No more than
50 ml of dextrose was used over the 10-rain period.
The blood samples were centrifuged and plasma stored at
-70 ° C. At th_ completion of the study, analysis was done
on all samples by a modified column extraction procedure
of Greenleaf and Hinghofer-Szalkay (1985) using
Sephadex columns (Pharmacia LKB Biotechnology,
Uppsala, Sweden) in place of Solka Floc columns.
Bloodvolumewascalculatedusingthesubject'sPVand
hematocrit(Hct)valueswithBV(inml)=PV(inml)x
{100/[100- (0.91x Hct)]}.
Blood Analyses
Hematocrit measurements were made using a micro-
hematocrit centrifuge (CT-2900, Adams Micro-
Hematocrit Centrifuge, Clay-Adams, Inc., N.Y.).
Vasopressin and catecholamine measurements for a sub-
ject were done in a single assay for each hormone. Vaso-
pressin (AVP) was measured by radioimmunoassay (RIA)
using the method of Keil and Severs (1977); the within-
assay coefficient of variability was 9% and assay
sensitivity was 0.3 pg/ml. Plasma norepinephrine (NE)
and epinephrine (E) were separated by high performance
liquid chromatography (HPLC) and then measured by
electrochemical detection (Bioanalytical Systems, West
Lafayette, Ind.); within-assay variabilities were 5% (NE)
and 3% (E) and sensitivities for both were 5 pg/ml (Wade
et al., 1991). Plasma renin activity (PRA) was measured
by RIA for angiotensin I (kit from New England Nuclear,
Boston, Mass.) with a within-assay coefficient of vari-
ability of 7%, an inter-assay coefficient of variability of
8%, and sensitivity of 30 ng/ml/hr. Aldosterone and corti-
sol were measured using RIA kits from Diagnostic Prod-
ucts Corporation (Los Angeles, Calif.); within-assay
coefficients of variability, inter-assay coefficients of vari-
ability, and sensitivities were 4%, 8%, and 2.5 ng/dl for
aldosterone and 3%, 4.4%, and 1 _g/100 ml for cortisol,
respectively. Atrial natriuretic peptide (ANP) was mea-
sured by Waters column extraction (Waters Chromatog-
raphy Division, Millipore Corporation, Milford, Mass.)
followed by RIA (kit from Peninsula Laboratories, Inc.,
Belmont, Calif.), with a within-assay coefficient of
variability of 5%, an inter-assay coefficient of variability
of 15%, and sensitivity of 1.5 pg/tube. Plasma Na and K
were measured by ion specific electrode (ISE) (Cobas
Mira, Roche Diagnostic Systems, Nutley, N.J.). Plasma
osmolality was measured using an Advanced Digimatic
Osmometer (Model 3D 11, Advanced Instruments, Inc.,
Needham Heights, Mass.). Serum total protein was
measured by hand refractometer (National, No. i 5064,
Japan) and serum creatinine by an alkaline picric acid
(APA) method (Cobas Mira, Roche Diagnostic Systems,
Nutley, N.J.). Total cholesterol, high density lipoprotein
(HDL) cholesterol, and triglyceride concentrations were
measured by an enzymatic chemistry procedure (Cobas
Mira, Roche Diagnostic Systems, Nutley, N.J.) and low
density lipoprotein (LDL) cholesterol was calculated
using the formula LDL cholesterol = Total cholesterol -
[HDL cholesterol + (Triglycerides/5)].
Urine Analyses:
Urinary creatinine was measured by APA (Cobas Mira,
Roche Diagnostic Systems, Nutley, N.J.) and the glomeru-
lar filtration rate (GFR) calculated using the formula
GFR = (Urinary creatinine excretion rate/Serum
creatinine)/1440. Urinary osmolality was measured using
an Advanced Digimatic Osmometer (Model 3DI l,
Advanced Instruments, Inc., Needham Heights, Mass.).
Urinary cortisol was measured using a RIA kit from
Diagnostic Products Corporation (Los Angeles, Calif.);
the within-assay coefficient of variability was 3%, the
inter-assay coefficient of variability was 4.4%, and
sensitivity was 1 lag/100 ml. Urinary Ca concentration
was measured by Arsenazo I11 colored complex (Cobas
Mira, Roche Diagnostic Systems, Nutley, N.J.) and
urinary Na and K were measured by ISE (Cobas Mira,
Roche Diagnostic Systems, Nutley, N.J.).
Statistics
The general experimental design consisted of nine sub-
jects who received five experimental treatments
(including no intervention). Each subject received each of
the five treatments (in random or near random order) and
were measured before and after each treatment. Some of
the dependent variables were measured over time (daily)
during HDBR. The general statistical model is therefore a
five treatment randomized block (subjects are the block-
ing factor) with two or five repeated measures. When only
two repeated measures were taken (pre- and post-
treatment), the repeated measures were differenced and
the differences were analyzed. This is equivalent to the
test of interaction in a standard repeated measures
ANOVA. The test of the difference scores evaluates
differences in the rate of change for the given dependent
variable across treatments after subject-to-subject
variation has been removed (subjects are crossed with
treatments). When more than two repeated measures were
taken, the rate of change was quantified by the slope of
the response across the repeated measures. The slopes
were either first order (linear) or second order (quadratic)
depending on the shape of the response function. These
slopes were then analyzed using the same model as the
difference scores. To correct for differences due to
starting points, slopes and differences were adjusted for
pre-HDBR values by analysis of covariance (pre-HDBR
values were used as a covariate). The statistical tests for
both slopes and differences evaluate the differences in rate
of change across the five treatments after correcting for
initial values. A more detailed description of this
approach is given by Laird (1983).
Line or bar charts were used for graphical analysis. Mean
variation is presented on the graphs as error bars (standard
errors).Estimatesof variationandmeanvaluesarebased
ontherawdata(dataspecifictothatmean)when osta-
tisticaltestwasperformed.Whenastatisticaltestwas
performed,pooledestimatesofvariationandadjusted
meansfromtheanalysisofcovariancearepresented•
Unadjustedmeansforallvariablesaregiveninthe
appendix.Specificomparisons(leastsignificantdiffer-
ences)betweentreatmentmeanswerecalculatedfromthe
poolederrorobtainedfromtheANCOVA.Intheeventof
missingobservations(duetosubjectwithdrawalor
equipmentfailure),statisticalestimateswereadjustedby
leastsquares.Sincethegenerallinearmodelwasthebasis
forallthestatisticalnalyses,adjustmentduetomissing
datawasinherenttothestatisticalmethodology.
Exactstatisticalprobabilities(TypeI errorates)aregiven
alongwiththesizeoftheteststatisticandthedegreesof
freedom.Thestatisticalprobabilitiescanbeinterpretedas
thechancesofobservingadifferenceaslargeorlarger
thantheoneobservedif in factthetreatmentshadno
effect.Thus,a lowprobability(Pvalue)Wouldindicatean
unusualsituationunderthehypothesisofnotreatment
differences.It mighthenbeconcludedthatheobserved
experimentaldifferenceisaresultoffactorsotherthan
randomexperimentalv riation.Inordertohelpcontrol
theexperimentwiseTypeI errorate,statisticaltestswere
onlyappliedtodependentvariablesofprimaryinterest
(orthostatictolerance,VO2peak,PV,urinaryCa).
Rawdataforalldependentvariablesareintheappendix.
Statistics:orthostatictolerance--Thestatisticalmethods
appliedtoHRandBPdatafromthetilt testaredifferent
fromthosedescribedaboveduetothelargeamountsof
data(beattobeat)collectedduringthetesting.Similarly,
analysisoffaintingrates(proportionfaintingduringthe
tilt test)requiredmorespecializedstatisticalprocedures
appropriatefortheanalysisofproportions.
Onediscreteandfourcontinuousmeasureswereusedas
dependentvariablesinquantifyingorthostaticintolerance.
Thediscretevariablewastheproportionoftheninesub-
jectswhosucces_fullyc0mpleieda_tilttestWithoutexpe-
riencing syncope or pre-syncopal symptoms ("survival
rate"). The four continuous variables were HR, mean arte-
rial pressure (MAP), and the two components of MAP,
systolic (SBP) and diastolic (DBP) pressures. The statisti-
cal analysis used the final 3 min prior to the 60 ° head-up
tilt as the control period. The tilt test lasted for 30 min.
Heart rate and BP (Finapres at heart level ata|i times)
were measured continuously before and during the tilt test
and digitally recorded every 3 sec on magnetic tape. This
equates to approximately 700 data points per subject per
variable. Fifteen sec averages were taken to reduce the
data to 140 data points per subject per variable. This time
series of 140 points occurring during the pre-tilt control
and the tilt test was used in the statistical analysis. Ten
"survival rates" (proportion completing a tilt test without
experiencing syncope or pre-syncopal symptoms) were
calculated from the five pre-HDBR (control) and the five
post-HDBR (treatment) tilt tests.
Statistical comparison of the pre-HDBR control measures
to the post-HDBR treatment conditions was accomplished
with the use of control charts (i.e., shewhart charts) and
multiple regression techniques (time series analysis). A
control chart was constructed for each of the five depen-
dent variables from the five pre-HDBR measurements.
This was possible since multiple control measures were
taken on the same subject prior to each HDBR exposure
and subsequent treatment. From this replicated pre-HDBR
information, variation in the physiological system when it
is functioning normally could be estimated. This inherent
variation (which also includes experimental variation and
measurement error) is graphically depicted in the form of
approximate 95% control limits on the control chart.
Experimental inference can then be made by comparing
the response under stress or during different treatments to
these limits. This statistical approach is similar to methods
described by Box et al. (1978) in that data internal to the
experiment is used as the reference distribution rather than
reference distributions based on normal theory (i.e., z, t,
F, etc.). A more detailed account of these statistical proce-
dures is given by Montgomery (1985).
Control charts for survival rate were constructed in the
same manner as those for HR and MAP. For comparative
purposes, a survival rate analysis based on asymptotic
normal theory was performed. The overall survival rate
from the five mUltiple Control periods Was tested against
each of the five treatment conditions using the Mantel-
Haenszel procedure for matched case control studies with
multiple con!r01s per case (Kleinbaum et al., 1982).
Results
Orthostatic Tolerance: Heart Rate And Blood
Pressure
The control charts for HR, MAP, SBP, and DBP are pre-
sented in figures !--4 respectively. Panel A of all four fig-
ures presents the average time series from the five pre-
HDBR measurements, ihe overall linear model, and the
approximate 95% control limits during the 30-min tilt test
(plus 3 min of supine pre-tilt). Panel B in each figure
compares the no intervention treatment (0 Gz) to the con-
trol limits while panels C and D compare the 2 and 4 hr
treatments to the control limits for both standing and
walking.
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Heart rate responses- The average pre-HDBR
(ambulatory control) HR response to tilt demonstrated an
increase in HR from 60 beats per minute (bpm) during
supine pre-tilt to 76 bpm at approximately 1 min post-tilt
(+16 beats) (fig. i, Panel A). Beats per minute continued
to increase at a rate of 0.56 beats/5min during tilt,
reaching an average maximum of 79 bpm by the end Of
the test. The 95% control limits were calculated at
approximately -+7 beats around the least squares fit of the
average time series (fig. I, Panel A).
The no intervention comparison (control HDBR with no
+ l G z exposure) was well outside the control limits indi-
cating a much different HR response to tilt after HDBR
(fig. 1, Panel B). The pre-tilt HR was elevated by approx-
imately 6 bpm (66 bpm) and rose to 102 bpm following
tilt (+36 bpm). At 1390 sec into tilt, three of the nine sub-
jects had failed the test. A slight survivor effect must be
considered when evaluating the no intervention series past
this point (i.e., only survivors are being evaluated during
the latter part of the tilt test).
The 2 hr stand and walk series (fig. I, Panel C) were also
outside the control limits. As with the no intervention
treatment, the supine HR was elevated by approximately
5 bpm rising to around 91 bpm following tilt (+26 beats).
Heart rate for the 2 hr stand tended to increase during tilt
in comparison to a somewhat constant HR for the 2 hr
walk treatment.
The 4 hr stand and walk series were also outside the con-
trol limits during tilt but showed a slight improvement
during pre-tiit (fig. l, Panel D). Both series jumped to
approximately 89 bpm following tilt (+25 beats) and
remained outside the control limits for the remainder of
the test. Heart rate for both 4 hr conditions remained reia-
tively constant during tilt. Although the 4 hr stand series
and 4 hr walk series were both outside the pre-HDBR
control limits, they showed a marked improvement over
the no intervention (0 Gz) treatment.
Although all the intervention treatments seemed to be an
improvement over no intervention, n0rie Of the treatments
completely restored HR response to pre-HDBR levels (all
fell outside the control limits). All of the 2 and 4 hr walk
and stand curves seemed comparable, except for a slightly
elevated HR (both pre- and post-tilt) for the 2 hr condi-
tions. Some possible interaction between exposure time
and activity level can be seen in Panels C and D of
figure 1. The HR for standing tends to be five to six beats
higher than that for walking given the 2 hr condition,
whereas little difference between standing and walking is
seen in the 4 hr condition. Although not statistically
discernible, perhaps activity is beneficial only when +Gz
exposure is low (i.e., low in duration and/or intensity).
Mean arterial pressure responses- Average supine
MAP during pre-HDBR was approximately 8 i mmHg ris-
ing to 99 mmHg (+l 8 mmHg) post-tilt (fig. 2, Panel A).
Mean arterial pressure continued to rise at a rate of
approximately 0.52 mmHg/5min during tilt reaching an
average maximum of approximately 103 mmHg by the
end 0ftIi6tesL The 95% control limits were calculated at
•+22 mmHg around the least squares fit of the average
time series (fig. 2, Panel A).
For the 0 Gz treatment, MAP remained within the 95%
control limits until the end of the tilt test (fig. 2, Panel B).
The overall series tended to remain in the lower quarter of
the control band through the majority of the test while
dropping to near pre-tilt values by the end of the test.
Supine pre-tilt values were slightly lower following
HDBR (approximately 3 mm/Hg).
Although pressure for both 2 hr conditions tended to drop
off at 1500 seconds, all of the intervention treatments
maintained pressure within the 95% control limits (fig. 2,
Panels C and D). As with HR, a slight interaction can be
seen. While the 4 hr curves are basically indistinguishable
and have slight positive slopes, the 2 hr curves begin to
separate and decline at 800 sec. Changes in MAP for the
2 hr conditions confirm changes observed in HR. While
the 2 hr standing condition produced higher HR than the
2 hr walk, the 2 hr walk produced greater pressure
increases than the 2 hr stand. This reflects the attempt to
compensate for lower pressure with higher HR.
Systolic blood pressure and diastolic blood pressure
responses- Similar results can be seen for SBP (fig. 3)
and DBP (fig. 4). Since MAP is a linear composite formed
from SBP and DBP, the responses across the tilt test, by
definition, would be similar.
Orthostatic Tolerance: Syncope Prevalence
The control chart and ManteI-Haenszel statistics for
"survival rates" (proportion of subjects completing a tilt
test without experiencing syncope or pre-syncopal symp-
toms) are presented in figure 5. Panel A of figure 5 gives
the survival rates for the five pre-HDBR tests and the five
post-HDBR treatments. Survival rates are based on nine
subjects except for both 2 hr conditions, where one sub-
ject dropped out of the study, and the 0 Gz condition,
where one subject became ill. Survival rates during pre-
HDBR ranged from 1.00 to 0.75 with an average survival
rate of 0,86. The lower bound of the approximate 95%
control limit calculated from the range and standard
deviation of the five pre-HDBR rates was 0.62,
[0.86 - i.96(0.12)]. The upper limit is bounded by 1.00.
This indicates that under normal ambulatory conditions it
would not be that unlikely that this sample of nine
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Figure 5. Tilt test survival rates (proportion completing the test) by treatment conditions for pre- and post-FIDBR
measurements (Panel A, survival rates and lower limit of the approximate 95% confidence interval; Panel B, Mantel-
Haenszel comparison of post-HDBR rates to the pre-HOBR average). The-traditional chi squared statistic was converted
to z for ease of interpretation (critical value of z = 1.96 for a Type I error rate of 0.05). Value of z statistics and associated
Type I probability levels are included in the figure. OG, $4, W4, $2, and W2_denote respectively the no treatment and the
4 hr stand, 4 hr walk, 2 hr stand, and 2 hr walk treatment conditions.
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subjects would vary in their respons6 [o_ihe tilt test
(survival rate) by as much as +24%. Thei'efore, until a
treatment demonstrated a decrease inz_lve_ge:_..,. survival rate
of at least 24%, the difference would riot be large enough
to conclude an effect when compared to normal variation
in survival rates when the subjects were ambulatory•
Panel B presents the results of the Mantel-Haenszel
comparisons of each post-HDBR survival rate to the
average pre-HDBR rate. The traditional chi squared
statistic was converted to z for ease of interpretation
(critical value of z = 1.96 for a Type I error rate of 0.05).
The results from both analyses show a decrease in sur-
vival rates (orthostatic tolerance) from pre-HDBR condi-
tions for the 0 G, 4 hr walk, and 2 hr walk, although the
2 hr walk condition was borderline. Both standing condi-
tions seemed to maintain pre-HDBR levels with the 4 hr
condition showing slightly better results. Walking did not
improve the survival rate as both walking conditions were
lower than both standing conditions. The results seem to
indicate that passive Gz provides more protection than
active Gz at least when compared to low level activity
(walking). Perhaps the active conditions were less effec-
tive due to a lower orthostatic challenge resulting from
augmented venous return during walking.
It Was expected that HR and BP data would to some
degree coincide with the survival rates. Only in the no
intervention condition (0 Gz) did this seem to be true.
Heart rate for the no intervention condition showed the
highest elevation during tilt and was associated with the
lowest survival rate. However, no relationship was seen
between HR or BP and survival rates within the four
intervention conditions.
Peak Oxygen Consumption
The results for the pre- to post-HDBR differences in
VO2pea k are given in figure 6. The 95% confidence
intervals around the treatment mean differences indicated
that a non zero decline in VO2pea k occurred across all
treatments (none of the confidence intervals included
zero). All of the intervention treatments (Ps < 0.0124)
demonstrated significantly smaller decreases in VO2pea k
than the 0 Gz condition. However, the 2 hr standing
treatment, although lower, was not significantly different
from the untreated condition (P = 0.1702). As expected,
the walking conditions showed less of a decrease than the
standing conditions. However, the 4 hr standing condition
was an improvement over the 0 Gz condition. The results
tended to favor the activity conditions with less of the
effect due to exposure time.
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Plasma Volume
The results for the pre- to post-HDBR difference in PV
are given in figure 7. Both 4 hr conditions showed less PV
loss by the end of HDBR as compared to the untreated,
0 Gz condition ($4: P = 0.0623; W4: P = 0.0383). No dif-
ference in PV change from pre- to post-HDBR was
detected between the 0 Gz and the 2 hr conditions
(P > 0.7375). The results indicate that treatment condi-
tions with a longer exposure time (4 hr) were most
effective, with little difference attributable to activity
(walking versus standing). However, the 4 hr walking
condition produced the least amount of pre- to post-
HDBR change (see adjusted means and confidence
intervals).
Urinary Calcium
Since urinary Ca was measured daily during HDBR, a
more complete analysis over days based on statistical
modeling was possible. Figure 8 (Upper Panels) presents
the actual urinary Ca output and actual % change in uri-
nary Ca by treatment condition and day. Figure 8 (Lower
Panel) gives the predicted urinary Ca based on a quadratic
polynomial model. Predicted urinary Ca was based on a
linear statistical model containing a constant, a linear, and
a quadratic term. The coefficients from the linear and
quadratic components for each treatment condition were
compared to access differences in response across HDBR.
This was done by estimating the linear and quadratic
terms for each subject and then testing the difference in
these terms across treatment conditions. As described in
the methods section, after the linear and quadratic coeffi-
cients were estimated for each subject, these coefficients
were analyzed with analysis of covariance holding the
initial Ca output (value at ambulatory control day)
constant.
Figure 9 presents the analysis of the linear component.
Although all of the treatment conditions showed a positive
linear increase in Ca excretion over HDBR days, the rate
of change was, for the most part, constant for all treatment
groups. On the average, the linear rate of change per day
was approximately 10 mg (see adjusted means and confi-
dence levels). The analysis of the quadratic component is
given in figure 10. This component represents the amount
of change (bend in the trend) over time. The results indi-
cate that the quadratic trend over time for the two standing
conditions (both 2 and 4 hr) was not different from the
trend for the 0 G condition (untreated). In contrast, the
two walking conditions were much flatter with only slight
positive quadratic trends (W2: P = 0.0109; W4:
P = 0.0262). (See fig. 8, Predicted Calcium.)
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Peak VO2
Adjusted* Mean Differences
(Pre- Minus Post-Bedrest)
O G S 2 W2 S 4 W4
SE(pooled) = .0384
* Adjusted for Pre-Bedrest Values. Overall F test for trealment differences
(ANCOVA) = 4.96; df = 4, 29; P = .0036.
Trealrnenl Adjusted Mean Dllference
Pre-Post Bedrest
Approximate 95%
Confidence Inlerval
Lower Limit Upper Limit
OG .4510 .3741 .5279
$2 .3703 .2934 .4472
W2 .2405 .1636 .3174
$4 .3054 .2285 .3823
W4 .2539 .1770 .3308
Pairwlse Comparisons (OG to Olher Treatments)
OG versus: Difference t(29)
$2 .0807 1.41 .1702
W2 .2105 3.70 .0009
$4 .1456 2.67 .0124
W4 .1971 3.60 .0012
Figure 6. Pre- to post-HDBR differences in VO2peak . OG, S2, W2, S4, and W4 denote respectively the no treatment and
the 2 hr stand, 2 hr walk, 4 hr stand, and 4 hr walk treatment conditions. Values are adjusted mean differencs +_SE
(pooled).
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Plasma Volurne
Adjusted* Mean Differences
(Pre- Minus Post-Bedrest)
OG S2 W2 S4 W4
SE(pooled) -- 55.84
* Adjusted for Pre-Bedrest Values. Overall F test for treatment differences
(ANCOVA) = 2.12; df = 4, 29; P = .1035.
Treatment Adjusted Mean Difference
Pre-Post Bedrest
Approximate 95%
Confidence Interval
Lower Limit Upper Limit
OG 282.98 171.30 394.66
$2 288.11 176.43 399.79
W2 254.47 142.79 366.15
$4 129.63 17.95 241.31
W4 107.58 -4.10 219.26
Pairwtse Comparisons (OG to Other Treatments)
OG versus: Difference t(29) P
$2 -5.14 -0.06 .7515
W2 28.51 0.34 .7375
$4 153.35 1.94 .0623
W4 175.40 2.17 .0383
Figure 7. Pre- to post-HDBR differences in plasma volume. OG, $2, W2, $4, and W4 denote respectively the no treatment
and the 2 hr stand, 2 hr walk, 4 hr stand, and 4 hr walk treatment conditions. Values are adjusted mean differences +_SE
(pooled).
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Figure 8. Actual (upper panels) and predicted (Iower panel) urinary calcium by treatment:conditionand HDBR days:
Values for actual and predicted urinary Ca are means; values for actual urinary Ca (% change) are means ._ SE. C I, BR 1,
BR2, BR3, and BR4 denote ambulatory control and HDBR days. OG, $2, S4, and W4 denote respectively the no
treatment and the 2 hr stand, 2 hr walk, 4 hr stand, and 4 hr walk treatment conditions.
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Urinary Calcium
Adjusted* Linear Coefficients
SE(pooled) = 2.83
O G S 2 W2 S 4 W4
* Adjusted for Pre-Bedrest Values. Overall F test for treatment differences
(ANCOVA) = 0.545; df = 4, 29; P = .7038.
Treatment Adjusted Mean
Linear Coefficients
Approximate 95%
Confidence Interval
Lower Limit Upper Limit
OG 7.35 1.56 13.14
$2 10.38 4.59 16.12
W2 7.82 2.03 13.61
$4 10.99 5.20 16.7B
W4 12.88 7.09 18.67
Pairwise Comparisons (OG to Otl_er Treatments)
OG versus: Difference t(29) _.P
S2 -3.03 -0.727 .4733
W2 -0.48 -0.109 .9142
$4 -3.64 -0.807 .4262
W4 -5.54 -1.190 .2433
Figure 9. Linear change in urinarycalciumby treatment conditionsduring HDBR. OG,$2, W2, S2, and W4 denote
respectively the no treatment and the 2 hr stand, 2 hr walk, 4 hr stand,and 4 hr walk treatmentconditions. Values are
means :_SE (pooled).
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Urinary Calcium
Adjusted* Quadratic Coefficients
SE(pooled) = 3.00
O G S 2 W2 S 4 W4
* Adjusted for Pre-Bedrest Values. Overall F test for treatment differences
(ANCOVA) = 3.82; df = 1, 29; P = .0130.
Treatmenl
OG
$2
W2
$4
W4
Adjusted Mean
Quadratic Coefficients
Approximate 95%
Confidence |nterval
Lower Limit Upper Limit
-g.36 -15.50 -3.23
-8.55 -14.69 -2.42
3.98 -2.46 10.12
-8.57 -14.71 -2.44
1.49 -4.65 7.63
Pairwlse Comparisons (OG to Other Treatments)
OG versus: Difference t(29) E
$2 -0.795 -0.18 .8580
W2 -13.346 -2.72 .0109
$4 -0.816 -0.17 .8652
W4 -10.850 -2.34 .0262
Figure 10. Quadraticchangein urinarycalcium by treatmentconditions during HDBR. OG,S2, W2, S4, and W4 denote
respectively the no treatment and the 2 hr stand,2 hr walk, 4 hr stand, and 4 hr walk treatment conditions. Values are
means +_SE (pooled).
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In summary, the two walking conditions attenuated the
increase in Ca output seen in the 0 G and standing condi-
tions. The 0 G and standing conditions showed a steady
increase in Ca excretion across HDBR which levelled off
by HDBR day 4. The walking conditions showed very lit-
tle trend as Ca output did not increase, and remained rela-
tively stable and comparable to values obtained prior to
HDBR (ambulatory control day).
Conclusions
Can cardiovascular deconditioning be attenuated with
periodic exposure to +1 Gz? The answer seems to depend
on which physiological variable is being evaluated and
how cardiovascular adaptation is defined. The results of
this study indicate that cardiovascular changes attributable
to HDBR can be attenuated to some degree by periodic
+1 Gz gravitational field (standing). Mild activity within
this field did seem to augment the effects of this
countermeasure although orthostatic intolerance was
attenuated to a greater extent by standing than walking.
Although this may at first seem surprising, the specificity
of the treatment in the standing conditions may have
allowed the subjects to maintain their orthostatic tolerance
in response to the tilt test, since standing imposed a
greater orthostatic challenge than walking because
walking contributes to venous return via the skeletal
muscle pump.
Although HR and BP were not restored completely to pre-
HDBR levels by any of the four treatments during HDBR,
the response (survival rate) to the tilt test in the subjects
when they stood 2 or 4 hr/day did return to what was typi-
cally observed during their ambulatory control, pre-
HDBR tilt tests. The control of BP during orthostatic
challenge involves complex physiological mechanisms.
The results here suggest that orthostatic intolerance can be
controlled even when peripheral cardiovascular measures
are altered. Indeed it is controlled because of appropriate
cardiovascular responses (Convertino, 1993). Compen-
satory mechanisms clearly allow for some alterations in
such cardiovascular indexes without complete loss of the
ability to maintain adequate bead level pressures. The data
also indicate that the orthostatic response in these subjects
following HDBR is mostly compensated for by an
increase in HR. Changes in BP were far less than those
seen for HR and in most cases fell within the control
limits.
A summary of the results is given in table 3. No single
treatment was most effective across all dependent vari-
ables. The results suggest that the preventive effects of
different countermeasures are system specific. As
expected, Ca balance responded favorably to activity in
+I G z whereas orthostatic tolerance and PV were less
dependent on activity and more dependent on the ortho-
static stimulus provided by the +G z field. It is not known
whether muscle and bone require additional G force inten-
sity over and above that provided by standing or whether
they respond specifically to activity whatever the G field.
The momentary high G stress and muscle activity pro-
vided by walking seem to be important components for
maintaining bone density and fitness (Whalen et al.,
1988).
In most cases, differences between the 2 and 4 hr expo-
sures were small. This suggests that 2 hr/day of standing
or walking would be sufficient to counteract the negative
effects of microgravity. In the case of Ca excretion, less
than 2 hr of walking may suffice. The most efficient time
schedule for this 2 hr of activity needs further investiga-
tion. Should the countermeasures be given in one 2-hr
dosage or should dosages of shorter duration (as we did
here) be given throughout the day? There is ample evi-
dence throughout physiology that systems respond to sig-
nal and intensity change rather than to the duration of the
stimulus. Factors such as fatigue, crew work
Table 3. Summary of results. $2, $4, W2, and W4 denote the 2 hr stand, 4 hr
stand, 2 hr walk, and 4 hr walk treatment conditions
$2 $4 W2 W4
Orthostatic intolerance ++
Peak _rO 2 +
Plasma volume o
Urinary calcium excretion (4 day) .o
+++ Most effective.
++ Effective.
+ Partially effective.
o Not effective.
+4"4- + O
++ _ ++"I-
-H'+ O +4-+
O +++ +4-4-
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schedules,andcrewsizeintherealenvironmentof
spaceflightwillalsoneedtobeconsidered.Using
centrifugationtoincreasetheintensityoftheGstimulus
furtherintroducesthepossibilityofundesirableCoriolis
sideeffects.Ideallytheshorterexposureswouldwork
bestfromaflightlogistics,psychological,ndcompliance
perspective.Futurestudiesinthisfieldmustassess
comprehensivephysiologicalchangesif theyareto
contributetoourunderstandingofGstimulus
requirements.
ThemosteffectiveandphysiologicallycomprehensiveG
replacementtreatmentisonethatismostlikewhatwe
experienceinoureverydaylifeonEarth,includingboth
passiveGzandGzwithactivity.Whatissurprisingishow
littleofthatexposurethehumanbodyseemstoneedto
maintainormalhealth.Whatevertheeventualoptimal
protocol,thepresentfindingsclearlyemphasizethatperi-
odicGzexposurecanadequatelypreventdeconditioning
associatedwithsimulatingtheeffectsofweightlessness.
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Appendix: Data Tables
i Height, cm ...............................................................................................................................................
2 Age, yr .....................................................................................................................................................
3 Weight, kg (Pre-HDBR) ..........................................................................................................................
4 Daily Weight, kg .....................................................................................................................................
5 Peak 40 2 submaximal and maximum heart rate (HR) in beats per min (bpm), where
"submaximal" is HR observed after 5 min at 400 kg-m/min ..................................................................
6 Peak 'JO 2, L/min ....................................................................................................................................
7 Peak "(/0 2, ml/kg/min (Pre-HDBR) .......................................................................................................
8 Peak _'O 2, ml/kg/min .............................................................................................................................
9 Orthostatic Tolerance, no faint (NF) or faint (F plus time into tilt at which
syncope occurred, rounded to nearest 15 seconds) .................................................................................
10 Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg),
Mean Arterial Pressure (mmHg), and Heart Rate (bpm) before and after a
60 ° head-up tilt test .................................................................................................................................
11 Plasma Volume, ml, determined using Sephadex Column method ........................................................
12 Plasma Volume, mi/kg ............................................................................................................................
13 Blood Hematocrit, Hct (%) .....................................................................................................................
14 Blood Volume, ml ............................................................................................. , ........................... i .........
15 Blood Volume, ml/kg ...................................... •.......................................................................................
16 Plasma AVP, pg/ml .................................................................................................................................
17 Plasma Norephinephrine (NE), pg/ml .....................................................................................................
18 Plasma Epinephrine (E), pg/ml ...............................................................................................................
19 PRA, ng/ml/hr .........................................................................................................................................
20 Plasma Aldosterone, ng/dl .......................................................................................................................
21 Plasma Corisol, p.g/100 ml ......................................................................................................................
22 Plasma ANP, pg/ml .................................................................................................................................
23 Plasma Sodium (Na), mEq/L ...................................................................................................................
Page
27
27
27
28
30
32
33
33
34
35
45
46
47
48
49
50
52
53
54
56
58
60
62
25
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
PlasmaPotassium(K),m/Eq/L...............................................................................................................
PlasmaOsmolality,mOsm/kg.................................................................................................................
SerumTotalProtein,g/dl........................................................................................................................
PlasmaTotalCholesterol,mg/dl.............................................................................................................
PlasmaHDLCholesterol,mg/dl.............................................................................................................
PlasmaLDLCholesterol,mg/dl.............................................................................................................
PlasmaTriglycerides,mg/dl....................................................................................................................
SerumCreatinine,mg/dl.........................................................................................................................
UrinaryCreatinine,rag/24hr..................................................................................................................
GlomerularFiltrationRate(GFR),dl/min...............................................................................................
UrinaryOsmolality,mOsm/kg................................................................................................................
Urinary Cortisol, jag/24 hr .......................................................................................................................
Urinary Calcium (Ca), mg/24 hr ....................................................................................
Sodium (Na) Intake, mEq/24 hr .......................................................................................................... i...
Urinary Sodium (Na), mEq/24 hr ............................................................................................................
Sodium (Na) Balance, mEq/24 hr, determined from Urinary Sodium (Na) minus
Sodium (Na) Intake .................................................................................................................................
Potassium (K) Intake, mEq/24 tar ............................................................................................................
Urinary Potassium (K), mEq/24 hr .........................................................................................................
Potassium (K) Balance, mEq/24 hr, determined from Urinary Potassium (K) minus
Potassium (K) Intake ..............................................................................................................................
Daily Fluid Intake, mi/24 hr ....................................................................................................................
Daily Fluid (Urinary) Output, ml/24 hr ...........................................................................................
Daily Fluid Balance, m1/24 hr, determined from Fluid Out minus Fluid In ...........................................
64
66
68
70
71
72
73
74
76
78
80
81
83
85
86
88
91
92
94
97
98
100
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Height , cm
Subject No.
435
439
434
420
243
279
405
394
249
0G
178
188
174
188
183
182
177
177
188
1GS4
178
188
174
188
183
182
177
177
188
1GW4
178
188
174
188
183
182
177
177
188
IGS2
178
188
174
188
183
177
177
188
IGW2
178
188
174
188
183
177
177
188
MEAN 182 182 182 182 182
SE 2 2 2 2 2
Age, yr
Subject No.
435
439
434
420
243
279
405
394
249
0G
37
40
35
46
31
33
42
38
35
MEAN 37
SE 2
1GS4
37
41
36
47
31
33
42
38
35
38
2
1GW4
37
40
36
46
32
33
42
38
35
38
1
1GS2
37
41
36
47
32
42
39
36
39
2
IGW2
37
41
36
47
32
42
38
36
39
2
Weight, k_ (Pre-HDBR)
Subject No. 0G
435 73.44
439 93.39
434 94.20
420 85.97
243 79.20
279 81.18
405 86.28
394 76.32
249 74.48
1GS4
74.82
97.73
92.47
86.56
80.11
81.43
87.42
76.42
74.48
1GW4
75.81
94.22
93.70
86.85
80.30
81.89
87.73
74.61
76.39
1GS2
76.65
101.00
95.31
86.14
76.67
85.75
77.70
74.46
1GW2
78.00
102.09
93.57
86.95
80.47
85.96
77.86
74.11
MEAN 82.72 83.49 83.50 84.21 84.88
!SE 2.58 2.71 2.50 3.44 3.30
i
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment condition and the 4 hr stand,
4 hr walk, 2 hr stand, and 2 hr walk treatment conditions.
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Daily Weight, kg
Subject No.
435
4391
434
420
243
279
405
394
249
0G 0G 0G 0G 0G 0G
C 1 BR 1 BR2 BR3 BR4 R+ 1
73.44 74.12 73.07 72.53 72.29 70.99
93.39 93.90 92.95 92.19 91.83 90.02
94.20 95.12 94.20 93.35 92.95 91.30
85.97 87.91 85.88 85.67 85.26 85.06
79.20 79.02 78.63 78.63 78.35 78.34
81.18 80.83 80.19 80.34 80.23 80.09
86.28 86.03 85.81 85.78 85.98 85.16
76.32 76.30 75.86 75.16 74.81 74.94
74.48 74.25 73.93 74.05 73.24 73.09
MEAN 82.72 83.05 82.28 81.97 81.66 81.00
SE 2.58 2.69 2.62 2.57 2.59 2.44
Daily Weight, kg
IGS4 1GS4 1GS4 IGS4 1GS4
Subject No.
435
439
434
420
243
279
405
394
249
1GS4
C 1 BR I BR2 BR3 BR4 R+ 1
74.82 75.03 74.84 75.32 73.65 73.56
97.73 97.10 97.15 96.47 95.97 96.37
92.47 92.08 92.46 92.55 91.87 91.78
86.56 86.33 86.74 87.18 86.59 86.59
80.11 80.09 80.92 79.88 79.53 78.47
81.43 81.84 81.30 81.41 80.98 79.88
87.42 87.71 87.34 88.03 87.15 86.76
76.42 76.15 75.97 75.72 74.96 74.95
74.48 74.46 74.13 74.00 74.08 73.88
MEAN 83.49 83.42 83.43 83.40 82.75 82.47
SE 2.71 2.65 2.69 2.69 2.70 2.76
Daily Weight, kg
Subject No.
435
439
434
420
243
279
405
394
249
1GW4 1GW4 1GW4 1GW4 1GW4 1GW4
C 1 BR 1 BR2 BR3 BR4 R+ 1
75.81 75.59 75.65 75.53 75.13 74.12
94.22 95.87 93.21 92.67 92.40 92.46
93.70 93.13 93.07 92.51 92.31 91.79
86.85 86.11 86.61 86.19 84.52 84.62
80.30 79.96 79.73 79.73 79.25 79.17
81.89 80.81 81.56 81.27 80.65 80.22
87.73 86.34 85.98 85.94 85.52 84.87
74.61 74.82 74.08 74.32 73.93 73.62
76.39 75.96 74.98 74.37 74.35 74.20
MEAN 83.50 83.18 82.76 82.50 82.01 81.67
SE 2.50 2.57 2.47 2.41 2.40 2.43
0(3, 1GS4, and 1GW4 denote respectively the no treatment condition and the 4 hr stand and 4 hr walk treatment
conditions. C1, BR1, BR2, BR3, BR4, and R+I denote ambulatory control, HDBR, and recovery days.
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Daily Weight, kg __"- _
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 IGS2 1GS2 1GS2 1GS2 IGS2
C 1 BR 1 BR2 BR3 BR4 R+ 1
76.65 76.87 77.16 76.87 76.54 76.29
101.00 100.97 101.07 100.39 100.20 99.58
95.31 95.29 95.22 95.04 94.15 94.31
86.14 86.91 86.10 86.40 85.99 85.96
76.67 76.76 76.95 77.35 76.48 76.48
85.75 85.37 85.15 85.04 84.75 84.41
77.70 77.53 78.27 78.24 77.27 76.95
74.46 74.64 73.71 74.23 73.75 73.72
_dEAN 84.21 84.29 84.20 84.20 83.64 83.46
SE 3.44 3.43 3.43 3.33 3.36 3.33
Daily Weight, kg
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 IGW2 1GW2 1GW2 IGW2 1GW2
CI BRI BR2 BR3 BR4 R+I
78.00 77.66 77.99 77.23 77.26 76.52
102.09 100.94 100.44 100.23 99.82 99.18
93.57 92.93 93.39 93.05 92.45 92.12
86.95 87.34 86.98 86.68 86.39 86.58
80.47 79.59 79.62 79.89 79.26 79.86
85.96 85.34 84.85 85.13 84.45 84.38
77.86 77.24 77.87 77.30 76.50 76.73
74.11 76.56 72.96 73.17 72.95 73.72
MEAN 84.88 84.70 84.26 84.09 83.64 83.64
SE 3.30 3.10 3.22 3.21 3.20 3.09
1GS2 and 1GW2 denote respectively the 2 hr stand and 2 hr walk treatment conditions. C1, BR1, BR2, BR3, BR4, and
R+I denote ambulatory control, HDBR, and recovery days.
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Peak VO2 submaximal and maximal heart rate (HR) in beats per min (bpm),
where "submaximal" is HR observed after 5 min at
400 kg-m/min
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G
Pre-BR Pre-BR Pos_BR Post-BR
Submaximal Max Submaximal Max
98 164 113 198
91 181 87 160
109 180 104 169
111 173 112 173
92 164 110 180
119 147 127 180
114 173 114 170
97 146 95 161
119 193 138 198
MEAN 106 169 111 177
SE 4 5 5 5
Peak VO2 submaximai and maximal heart rate (HR) in beats per min (bpm),
where "submaximal" is HR observed after 5 min at
400 kg-m/min
ISubject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
1GS4 IGS4 1GS4 IGS4
Pre-BR Pre-BR Post-BR Post-BR
Submaximal Max Submaximal Max
106 169 106 170
105 169 101 177
112 169 107 167
129 172 118 172
96 167 100 178
124 168 118 158
116 172 117 167
93 143 95 157
135 i89 134 200
113 169 111 172
5 4 4 4
0(3 and 1GS4 denote respectively the no treatment and the 4 hr stand treatment
conditions. Pre-BR and Post-BR denote pre- and post-HDBR.
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Peak VO2 submaximal and maximal heart rate (HR) in bea _ per rain (bpm),
Subject No.
435
439
434
420
243
279
405
394
249
where "submaximal" is HR observed after 5 min at
400 kg-m/min
1GW4 1GW4 1GW4 1GW4
Pre-BR Pre-BR Post-BR Post-BR
Submaximal Max Submaximal Max
115 169 105 185
100 173 95 171
110 180 100 160
115 168 114 163
174 101 175
110 151 111 153
125 167 118 165
111 164 100 158
117 189 132 193
i_IEAN 113 171 108 169
SE 2 4 4 4
Peak VO2 submaximai and maximal heart rate (HR) in beats per rain (bpm),
where "submaximal" is IIR observed after 5 rain at
400 kg-m/min
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2 IGS2 1GS2
Pre-BR Pre-BR Post-BR Post-BR
Submaximal Max Submaximal Max
104 17,1 125 177
99 178 107 160
101 164 107 150
121 170 115 171
99 178 93 179
101 168 116 175
109 153 104 175
127 191 140 191
MEAN 108 172 113 172
SE 4 4 5 4
1GW4 and 1GS2 denote respectively the 4 hr walk and 2 hr stand treatment
conditions. Pre-BR and Post-BR denote pre- and post-HDBR.
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Peak VO2 submaximal and maximal heart rate (HR) in beats per min (bpm),
where "submaximar' is HR observed after 5 min at
400 kg-m/min
Subject No.
435
439
434
420
243
279
405
394
2491
1GW2 1GW2 1GW2 1GW2
Pre-BR Pre-BR Post-BR Post-BR
Submaximal Max Submaximal Max
102 164 118 183
105 168 98 170
99 156 100 174
125 174 115 187
107 181 100 167
95 161 93 161
104 146 100 150
133 199 192
MEAN 109 169 103 173
SE 5 6 3 5
Peak VO2, L/min
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Pre-BR Post-BR
2.30 1.97
2.87 2.38
2.44 1.74
2.03 1.81
3.22 2.81
2.27 1.80
3.31 2.70
2.58 2.22
2.94 2.54
1GS4 IGS4
Pre-BR Post-BR
2.33 2.15
2.88 2.64
2.33 2.00
2.10 1.95
3.01 2.95
2.48 1.98
3.24 2.77
2.81 2.18
3.09 2.78
MEAN 2.66 2.22 2.70 2.38
SE 0.15 0.14 0.13 0.13
1GW4 1GW4
Pre-BR Post-BR
2.50 2.37
2.69 2.47
2.33 2.14
2.15 1.97
3.35 3.08
2.21 2.00
2.98 2.72
2.76 2.15
3.37 2.99
2.70 2.43
0.15 0.14
0G, IGS4, 1GW4, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, and 2 hr walk
treatment conditions. Pre-BR and Post-BR denote pre- and post-HDBR.
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iPeak VO2, L/rain
iGW2
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Pre-BR Post-BR
2.30 2.14
2.84 2.51
2.38 2.00
1.99 1.98
3.16 2.74
3.23 2.71
2.54 2.23
2.70 2.30
2.64 2.33
0.15 0.11
IGW2
Pre-BR Post-BR
2.28 2.15
3.10 2.65
2.00 2.11
2.01 1.90
3.32 3.18
3.13 2.74
2.58 2.50
2.88 2.48
2.66 2.46
0.18 0.14
Peak VO2, mi/kg/min (Pre-HDBR)
Subject No.
435
439
4341
420
243
279
405
394
249
O(3
31.8
30.8
26.0
23.4
41.1
27.6
38.8
33.8
38.5
1GS4
31.7
29.2
25.0
24.0
37.5
30.3
37.1
35.9
40.9
IGW4
32.9
28.5
24.8
24.7
41.8
27.1
34.2
36.7
44.2
1GS2
30.0
27.4
24.9
23.0
39.9
38.2
31.8
36.4
1GW2
29.3
30.2
21.4
23.0
41.3
36.7
32.6
39.0
MEAN 32.4 32.4 32.8 31.5 31.7
SE 2.1 1.9 2.4 2.2 2.5
Peak VO2, ml/kg/min
IGw4
Subject No.
435
439
434
420
243
279
405
394
249
0G 0<3
Pre-BR Post-BR
31.8 27.3
30.8 25.9
26.0 18.8
23.4 21.2
41.1 35.9
27.6 22.6
38.8 31.5
33.8 29.7
38.5 34.8
IGS4 1GS4
Pre-BR Post-BR
31.7 29.2
29.2 27.6
25.0 21.9
24.0 22.5
37.5 37.1
30.3 24.5
37.1 31.9
35.9 29.1
40.9 37.5
1GW4
Pre-BR Post-BR
32.9 31.6
28.5 26.8
24.8 23.3
24.7 23.3
41.8 38.9
27.1 24.8
34.2 31.9
36.7 29.1
44.2 40.3
MEAN 32.4 27.5 32.4 29.0 32.8 30.0
SE 2.1 2.0 1.9 1.9 2.4 2.1
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Pre-BR and Post-BR denote pre- and post-HDBR.
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Peak V02, ml/kg/min
Subject No.
MEAN
SE
1GS2 1GS2
Pre-BR Post-BR
30.0 28.0
27.4 25.1
24.9 21.2
23.0 23.1
39.9 35.9
435
439
434
420
243
279
405
394
249
38.2 32.0
31.8 29.0
36.4 31.2
31.5 28.2
2.2 1.7
IGW2 IGW2
Pre-BR Post-BR
29.3 27.9
30.2 26.6
21.4 22.9
23.0 22.0
41.3 40.2
36.7 32.4
32.6 32.7
39.0 34.0
31.7 29.8
2.5 2.2
Orthostatic Tolerance, no faint (NF) or faint (17 plus time into tilt at which syncope occurred, rounded to
nearest 15 seconds)
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Pre-BR Post-BR
NF NF
FLU (2:30) F(lI:I5)
NF NF
NF NF
NF F (11:00)
F (12:30) F (17:30)
NF F (25:00)
NF F (3:30)
F (I0:15) F (29:45)
1GS4 IGS4
Pre-BR Post-BR
NF NF
NF NF
NF NF
NF NF
NF NF
NF NF
NF NF
NF NF
NF F (14:30)
1GW4
Pre-BR
NF
NF
NF
NF
NF
NF
NF
F (5:45)
F (10:45)
1GW4
Post-BR
NF
F (14:15)
NF
F (21:00)
NF
F (6:30)
NF
NF
F (14:30)
Orthostatic Tolerance, no faint (NF) or faint (F plus time into tilt at which syncope occurred, rounded to
nearest 15 seconds)
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Pre-BR Post-BR
NF NF
NF NF
NF NF
NF NF
NF NF
NF NF
NF F (17:45)
NF F (10:00)
1GW2 IGW2
Pre-BR Post-BR
NF NF
NF F (20:15)
NF NF
NF NF
NF NF
NF NF
F (10:00) F (9:30)
F (21:00) F (10:30)
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no lleatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Pre-BR and Post-BR denote pre- and post-HDBR.
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4 k
Tilt Test: Systolic Blood Pressure (_mHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm).before and after a 60° head-up tilt test
0G Condition (Pre-HDBR)
Systolic Blood Pressure, mmHg
[Subject No.
435!
439!
434!
420
243
279
405
394
249
Pre-Tilt
119
106
121
98
98
120
122
118
Test End Point
131
120
113
106
75
131
161
69
(130)
023)
(113)
(97)
(83)
Diastolic Blood Pressure, mmHg
Pre-Tilt
56
61
64
58
57
88
90
76
Test End Point
71
76
71
69
49
90
88
36
(7o)
(79)
(71)
(64)
(54)
MEAN 113 113 (109) 69 69 (68)
SE 4 11 (9) 5 6 (4)
IMean Arterial Pressure, mmHg Heart Rate, bpm
Subject No.
435
439
434
420
243
279
4O5
394
249
Pre-Tih
75
72
82
70
69
99
101
90
Test End Point
85
87
84
78
56
104
112
47
(85)
(90)
(84)
(72)
(62)
Pre-Tilt
53
63
65
47
71
6O
60
69
Test End Point
67 (71)
92 (93)
83 (84)
81 (77)
68 (73)
70
64
59
MEAN 82 82 (79) 61 73 (80)
SE 5 8 (5) 4 4 (4)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 min or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test. Pre-Tilt and Test End Point values for
Subjects #249, #394, #405 for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR)
are single point hand recorded values; Mean Arterial Pressure (MAP) for these subjects was calculated using the
formula: MAP = (SBP - DBP)/3 + DBP. Measurements for Subject #439 were not used: data was deleted because
subject had fever and fainted at 2:30 rain.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60 ° head-up tilt test
0G Condition (Post-HDBR)
!Systolic Blood Pressure, mmHg
Subject No.
435
439
434
420
243
279
405
394
249
Pre-Tilt
125
117
113
116
111
96
107
131
112
Test End Point
118 (118)
96 (96)
97 (97)
lO6 (lO9)
73 (59)
114 (100)
77 (78)
96 (103)
118 (112)
Diastolic BIll Pressure, mmHg
Test End PointPre-Tilt
71
72
56
54
62
49
84
69
65
68 (68)
66 (66)
67 (67)
77 (78)
50 (43)
77 (67)
72 (69)
52 (58)
69 (68)
MEAN 114 99 (97) 65 66 (65)
SE 3 5 (6) 4 3 (3)
Mean Arterial Pressure, mmHg Heart Rate, bpm
Subject No.
435
439i
434
420
243
279
405
394
249
Pre-Tilt
87
87
70
73
77
61
93
87
81
Test End Point
80 (80)
73 (73)
75 (75)
83 (86)
56 (47)
87 (76)
72 (71)
62 (69)
88 (85)
Pre-Tilt
60
69
65
66
50
77
67
63
77
MEAN 80 75 (74) 66 94 (97)
SE 3 4 (4) 3 8 (5)
Test End Point
1o4 (lO4)
85 (85)
108 (108)
111 (111)
90 (99)
124 (117)
44 (70)
83 (83)
96 (92)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 min or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test. Test End Point values for Subjects #439,
#435, #434 are averages of measurements taken in the final 15-sec period of the test before completion of the test.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) .be.fore and after a 60 ° head-up tilt test
$4 Condition (Pre-HDBR)
Systolic Blood Pressure, mmHg Diastolic Blood Pressure, mmHg
Subject No. Test End Point
435
439
434
420
243
279
405
394
249
Pre-Tilt
120
112
88
98
119
118
128
132
126
Test End Point
138 (136)
136 (137)
112 (122)
148 (141)
139 (130)
135 (131)
170 (172)
175 (175)
123 (122)
Pre-Tilt
78
52
36
48
74
60
81
85
84
89 (88)
83 (82)
73 (72)
99 (94)
86 (84)
81 (78)
113 (113)
ll5 (llS)
88 (88)
MEAN 116 142 (141 ) 66 92 (90)
SE 5 7 (7) 6 5 (5)
Mean Arterial Pressure, mmHg Heart Rate, bpm
Subject No. Pre-Tilt
435
439
434
420
243
279
405
394
249
Pre-Tilt
94
70
47
65
87
75
98
101
100
Test End Point
lO4 (102)
97 (97)
82 (83)
114 (107)
97 (94)
94 (91)
130 (131)
133 (133)
1130 (99)
MEAN 82 I06 (104)
SE 6 6 (6)
56
61
53
64
51
82
60
60
80
Test End Point
70 (73)
79 (78)
87 (80)
98 (99)
63 (75)
102 (104)
67 (67)
69 (69)
102 (101)
63 82 (83)
4 5 (5)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 min or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test. Test End Point values for Subject #394 are
averages of measurements taken in the final 15-sec period of the test before completion of the test.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60° head-up tilt test
$4 Condition (Post-HDBR)
Systolic Blood Pressure, mmHg Diastolic Blood Pressure, mmHg
Subject No.
435
439
434
,i2o
243
279
405
394
249
Pre-Tilt
118
98
102
107
97
121
115
121
119
Test End Point
81 (92)
133 (136)
101 (98)
142 (136)
106 (107)
122 (125)
148 (147)
142 (143)
119 (100)
Pre-Tilt Test End Point
58
55
42
64
57
76
84
75
84
55 (60)
85 (88)
61 (58)
95 (92)
69 (71)
95 (97)
105 (104)
94 (95)
90 (84)
MEAN 111 122 (120) 66 83 (83)
SE 3 7 (7) 5 6 (6)
Mean Arterial Pressure, mmHg Heart Rate, bpm
Subject No.
435
439
434
420
243
279
405
394
249
Pre-Tilt
76
69
58
81
70
89
97
90
98
Test End Point
62 (69)
98 (101)
70 (68)
110 (105)
78 (80)
103 (105)
119 (118)
107 (107)
98 (88)
Pre-Tilt
68
68
56
64
61
72
62
60
73
Test End Point
104 (104)
87 (89)
102 (101)
94 (92)
95 (99)
116 (116)
75 (74)
86 (86)
112 (90)
MEAN 81 94 (93) 65 97 (95)
SE 5 6 (6) 2 4 (4)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 rain or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60 ° head-up tilt test
W4 Condition (Pre-HDBR)
435
439
434
420
243
279
405
394
249
Subject No.
Systolic Blood Pressure, mmHg Diastolic Blood Pressure, mmHg
Pre-Tilt
138
114
108
134
124
99
138
141
154
Test End Point
155 (158)
137 (136)
132 (132)
133 (125)
145
128
165 (165)
62 (67)
58 (62)
Pre-Tilt
92
65
61
86
56
48
101
77
96
Test End Point
109 (! 12)
87 (87)
89 (89)
91 (87)
88
84
117 (117)
32 (35)
32 (35)
MEAN 128 124 (121) 76 81 (80)
SE 6 13 (15) 6 10 (13)
Mean Arterial Pressure, mmHg
Subject No.
435
439
434
420
243
279
405
394
249
Pre-Tilt
109
81
72
102
79
60
114
97
115
Test End Point
124 (127)
100 (101)
97 (97)
102 (98)
107
99
134 (134)
40 (43)
41 (44)
Test End Point
70 (67)
78 (79)
84 (84)
94 (92)
76
81
66 (66)
64 (67)
37 (38)
Heart Rate, bpm
Pre-Tilt
56
60
61
74
77
52
63
70
64
3
MEAN 92 94 (92) 72 (70)
SE 7 11 (14) 5 (7)
Pre-Tilt values are averages of measurements taken in the 15-second period proceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 min or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test. Test End Point values for Subjects #434,
#405 are averages of last 15 second measurements. Pre-Tilt and Test End Point values for Subject #243 and Test End
Point values for Subject #279 for Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate
(HR) are single point hand recorded values; Mean Arterial Pressure (MAP) for these subjects was calculated
according to the formula: MAP = (SBP - DBP)/3 + DBP.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg)' Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60 ° head-up tilt test
W4 Condition (Post-HDBR)
Systolic Blood Pressure, mmHgg ..... Diastolic Blood Pressure, mmHg
Subject No.
435
439
434
420
243
279
405
394
249
Pre-Tilt
120
101
100
101
85
82
129
133
134
Test End Point
131 (127)
103 (105)
115 (lO9)
61 (61)
83 (92)
66 (65)
141 (141)
164 (160)
119 (119)
Pre-Tilt
65
55
60
58
47
45
93
77
71
Test End Point
74 (76)
67 (69)
71 (72)
43 (42)
65 (70)
38 (39)
108 (io9)
112 008)
66 (66)
MEAN 109 109 (109) 63 72 (72)
SE 7 12 (11) 5 8 (8)
Mean Arterial Pressure, mmHg Heart Rate, bpm
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
Pre-Tilt
83
70
71
74
59
56
106
93
91
78
6
Test End Point
88 (89)
75 (77)
81 (80)
49 (49)
69 (76)
45 (47)
117 (118)
125 (121)
86 (85)
82 (82)
9 (9)
Pre-Tilt
68
64
68
63
53
59
65
67
73
64
2
Test End Point
94 (94)
85 (88)
92 (94)
72 (75)
11o (111)
86 (85)
76 (79)
92 (89)
56 (56)
85 (86)
5 (5)
Pre-Tiit values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken.at completion of the test (30 rain or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60 ° head-up tilt test
$2 Condition (Pre-HDBR)
Systolic Blood Pressure, mmHg
Subject No.
435
439
434
420
2,#3
279
405
394
249
Pre-Tilt
120
98
95
105
117
108
141
104
Test End Point
153
154
129
161
131
(151)
(158)
(129)
(157)
(140)
147 (148)
174 (180)
143 (140)
:Diastolic Blood Pressure, mmHg
Pre-Tiit Test End Point
77 97
60 93
52 78
53 84
57 67
71 94
76 99
60 89
63 88
4 4
(96)
(94)
(83)
(90)
(75)
(96)
(106)
(92)
MEAN 111 149 (150) (92)
ISE 5 5 (5) (3)
ISubject No.
435
439
434
420
243
279
405
394
249
Mean Arterial Pressure, mmHg
Pre-Tilt
90
70
63
70
74
86
95
76
Test End Point
114 (112)
lO9 (11o)
90 (94)
106 (109)
81 (90)
i l I (114)
121 (128)
103 (104)
Heart Rate, bpm
Pre-Tilt
57
56
57
66
49
56
58
72
Test End Point
80 (80)
74 (73)
70 (80)
89 (91)
71 (75)
62 (62)
69 (69)
90 (91)
MEAN 78 104 (108) 59 76 (78)
SE 4 5 (4) 2 4 (4)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 min or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60 ° head-up tilt test
$2 Condition (Post-HDBR)
Systolic Blood Pressure, mmHg Diastolic Blood Pressure, mmHg
Subject No.
435
439
434
420
243
279
405
394
249
Pre-Tilt
112
105
92
113
122
109
133
107
Test End Point
138 (128)
100 (105)
101 (91)
135 (143)
117 (114)
133 (135)
97 (209)
77 (79)
Pre-Tilt
60
54
56
49
80
69
96
63
Test End Point
83 (82)
52 (58)
56 (61)
82 (85)
95 (95)
89 (94)
82 (156)
50 (51)
MEAN 112 112 (126) 66 74 (85)
SE 4 8 (14) 5 6 (12)
[Mean Arterial Pressure, mmHg Heart Rate, bpm
Subject No.
435
439
434
420
243
279
405
394
249
Pre-Tilt
76
69
65
69
89
84
108
77
Test End Point
97 (93)
63 (69)
67 (68)
95 (100)
lOO (lOl)
104 (106)
86 (170)
58 (61)
Pre-Tilt
61
61
62
67
65
61
67
78
Test End Point
108 (110)
87 (86)
88 (99)
110 (112)
ioo (1o3)
84 (81)
77 (96)
110 (100)
MEAN 80 84 (96) 65 96 (98)
SE 5 6 (12) 2 5 (4)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 min or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test.
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iTilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg),'_dean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60 ° he adu p tilt test
W2 Condition (Pre-HDBR)
Systolic Blood Pressure, mmHg Diastolic Blood Pressure, mmHg
Subject No.
435
439
434
420
243
279
405
394
249
Pre-Tilt
117
117
85
95
98
109
144
115
Test End Point
164 (168)
161 (155)
I06 (102)
141 (144)
136 (139)
152 (156)
78 (84)
112 (114)
Pre-Tilt
67
69
41
53
46
60
82
66
Test End Point
90 (96)
96 (98)
57 (63)
90 (91)
78 (76)
82 (87)
42 (44)
56 (57)
MEAN 110 131 (133) 61 74 (77)
SE 6 11 (I0) 5 7 (7)
Mean Arterial Pressure, mmHg
Subject No. Test End Point
MEAN
SE
435
439
434
420
243
279
405
394
249
Pre-Tilt
85
80
53
69
61
77
102
83
76
5
Test End Point
114 (119)
109 (111)
68 (72)
105 (107)
89 (89)
104 (107)
51 (54)
75 (77)
89 (92)
8 (8)
Heart Rate, bpm
Pre-Tilt
58
62
56
55
44
53
58
69
57
3
75 (74)
80 (79)
80 (81)
75 (78)
71 (65)
64 (63)
68 (67)
65 (65)
72 (72)
2 (3)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test (30 min or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test.
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Tilt Test: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Mean Arterial Pressure
(mmHg), and Heart Rate (bpm) before and after a 60 ° head-up tilt test
W2 Condition (Post-HDBR)
Systolic Blood Pressure, mmHg Diastolic Blood Pressure, mmHg
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
Pte-Tilt
106
115
109
102
113
95
128
108
110
3
Test End Point
145 (147)
110 (115)
117
133 (138)
127 (123)
136 (136)
107 (118)
68 (77)
118 (122)
8 (9)
Pre-Tilt
61
74
68
57
62
58
68
52
63
3
Test End Point
77 (87)
73 (73)
79
81 (91)
88 (86)
82 (88)
65 (73)
40 (46)
73 (78)
5 (6)
Subject No.
435
439
434
420
243
279
405
394
249
Mean Arterial Pressure, mmHg Heart Rate, bpm
Pre-Tilt
73
84
82
74
77
71
84
69
Test End Point
97 (104)
85 (84)
92
99 (107)
99 (96)
98 (101)
76 (85)
48 (55)
Pre-Tilt
67
72
67
55
Test End Point
82 (89)
93 (86)
104
89 (90)
98 (94)
58
65
75
74 (76)
87 (89)
88 (88)
MEAN 77 87 (90) 66 89 (87)
SE 2 6 (7) 3 3 (2)
Pre-Tilt values are averages of measurements taken in the 15-second period preceeding one minute before start of tilt.
Test End Point values are single point measurements taken at completion of the test 30 rain or syncope). Parenthetic
end point values are an average over the last 15 seconds prior to end of test. Pre-Tilt and Test End Point values for
Subject #434 and Test End Point values for Subject #439 for Systolic Blood Pressure (SBP), Diastolic Blood
Pressure (DBP), and Heart Rate (HR) are single point hand recorded values; Mean Arterial Pressure (MAP) for
these subjects was calculated according to the formula: MAP = (SBP - DBP)/3 + DBP.
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Plasma Volume, ml, determined using Sephadex Column method
Subject No.
435
439:
434
420
243!
279
405
394J
249
0G 0G
Ambulatory
Control BR4
3322.4 3090.7
2511.2 2483.4
2201.1 2051.8
2294.1 2235.4
3031.6 2595.9
3418.6 2732.2
2956.4 2380.5
2405.8 2023.3
2031.1 1929.7
1GS4 IGS4
Ambulatory
Control BR4
2993.1 2875.8
2862.3 2747.3
2204.9 2066.2
2332.5 2274.0
2990.4 3080.4
2286.3 2152.2
3370.3 2854.6
2065.7 2021.0
2361.5 2274.6
1GW4
Ambulatory
Control
2314.6
3970.1
2497.2
3866.8
2917.5
1905.8
2469. I
2559.0
4387.9
1GW4
BR4
1776.0
3788.4
2364.5
3603.9
2870.0
2093.8
2599.3
2134.0
4016.0
MEAN 2685.8 2391.4 2607.4 2482.9 2987.6 2805.1
SE 169.2 126.0 150.8 134.5 289.2 272.0
Plasma Volume, ml, determined using,Sephadex Column method
1GS2 IGS2
Ambulatory
Subject No. Control BR4
435 2426.2 2241.9
439 2804.6 2585.4
434 2179.7 2093.2
420 2196.1 2108.5
243 2345.7 2291.8
279
405
394
249
2957.9 2347.8
2402.3 2014.8
2194.4 1901.2
1GW2 IGW2
Ambulatory
Control BR4
2322.2 2286.3
3026.9 2968.4
2312.4 1964.0
2253.5 2189.1
2159.7 1961.3
2719.7 2210.9
2299.2 2072.1
2031.8 1900.4
MEAN 2438.4 2198.1 2390.7 2194.1
SE 103.4 76.1 114.4 120.8
0(3, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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'Plasma Volume, ml/kg
OG 1GS4 1GW4
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
45.2 42.8
26.9 27.0
23.4 22.1
26.7 26.2
38.3 33.1
42.1 34.1
34.3 27.7
31.5 27.0
27.3 26.3
32.8 29.6
2.5 2.0
1GS4
Ambulatory
Control BR4
40.0 39.0
29.3 28.6
23.8 22.5
26.9 26.3
37.3 38.7
28.1 26.6
38.6 32.8
27.0 27.0
31.7 30.7
31.4 30.2
1.9 1.9
1GW4
Ambulatory
Control
30.5
42.1
26.7
44.5
36.3
23.3
28.1
34.3
57.4
35.9
3.6
BR4
23.6
41.0
25.6
42.6
36.2
26.0
30.4
28.9
54.0
34.3
3.4
Plasma Volume, mi/kg
1GS2 IGW2 1GW2
Subject No.
435
439
434
420
243
279
405
394
249
1GS2
Ambulatory
Control BR4
31.7 29.3
27.8 25.8
22.9 22.2
25.5 24.5
30.6 30.0
34.5 27.7
30.9 26.1
29.5 25.8
Ambulatory
Control BR4
29.8 29.6
29.6 29.7
24.7 21.2
25.9 25.3
26.8 24.7
31.6 26.2
29.5 27.1
27.4 26.1
MEAN 29.2 26.4 28.2 26.2
SE 1.3 0.9 0.8 1.0
0G, 1GS4, IGW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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iBlood Hematocrit, Hct (%) :: = =
0(3 1GS4 1GW4
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control
47.0
41.5
46.0
41.5
45.0
46.0
38.0
43.0
42.0
43.3
1.0
BR4
52.5
45.5
49.5
41.0
47.5
47.0
41.5
48.0
47.0
46.6
1.2
1GS4
Ambulatory
Control
49.0
43.5
44.5
40.0
45.1
46.0
36.9
46.5
45.5
BR4
52.0
43.0
45.5
38.0
45.0
45.5
38.5
47.0
46.0
44.1 44.5
1.2 1.4
1GW4
Ambulatory
Control
48.0
42.0
45.0
38.0
44.0
43.5
39.0
45.0
45.0
43.3
1.1
BR4
50.5
44.0
45.5
38.0
45.0
44.0
40.0
45.0
44.5
44.1
1.2
Blood Hematocrit, Hct (%)
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
1GS2 1GS2
Ambulatory
Control BR4
48.5 50.0
41.8 44.0
38.8 41.5
38.0 40.0
45.0 48.0
39.5 43.5
45.0 49.0
45.0 47.5
1GW2 1GW2
Ambulatory
Control BR4
48.0 47.5
42.0 44.0
43.0 47.0
39.0 40.5
44.0 48.5
38.8 41.5
46.0 48.8
45.0 46.0
42.7 45.4 43.2 45.5
1.3 1.3 1.1 1.1
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Blood Volume, ml
0(3 1GS4 IGW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
5805.4 5918.1
4035.0 4238.2
3785.9 3733.6
3686.2 3565.8
5134.0 4572.3
5880.0 4774.0
4519.1 3825.0
3952.4 3592.5
3287.6 3371.8
1GS4
Ambulatory
Control BR4
5401.7 5459.0
4737.7 4513.4
3705.4 3526.2
3667.5 3476.0
5072.0 5216.5
3932.4 3673.1
5074.1 4394,0
3581.0 3531.3
4030.3 3912.3
IGW4
Ambulatory
Control
4109.7
6426.1
4229.0
5910.7
4865.7
3154.5
3827.5
4333.6
7430.8
BR4
3286.2
6318.3
4035.4
5508.9
4860.3
3492.1
4086.9
3614.0
6748.9
MEAN 4454.0 4176.8 4355.8 4189.1 4920.8 4661.2
SE 315.1 269.6 237.2 251.1 461.7 423.9
Blood Volume, ml
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
IGS2 1GS2
Ambulatory
Control BR4
4343.0 4113.6
4526.3 4311.9
3369.4 3363.4
3356.9 3315.3
3972.4 4069.2
4617.8 3886.1
4068.2 3636.2
3716.2 3348.7
3996.3 3755.6
172.9 138.9
1GW2 1GW2
Ambulatory
Control BR4
4123.2 4026.9
4899.5 4950.6
3798.9 3431.8
3493.3 3466.8
3601.9 3510.8
4204.1 3552.5
3954.6 3727.3
3440.8 3268.7
3939.5 3741.9
169.4 190.3
0G, IGS4, IGW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Blood Volume, ml/kg
O(3
Ambulatory
Subject No. Control
435 79.0
439 43.2
434 40.2
420 42.9
243 64.8
279 72.4
405 52.4
394 51.8
249 44.1
MEAN 54.5
SE 4.7
0G
BR4
81.9
46.2
40.2
41.8
58.4
59.5
44.5
48.0
46.0
1GS4 IGS4
Ambulatory
Control BR4
72.2 74.1
48.5 47.0
40.1 38.4
42.4 40.1
63.3 65.6
48.3 45.4
58.0 50.4
46.9 47.1
54.1 52.8
1GW4
Ambulatory
Control
54.2
68.2
45.1
68.1
60.6
38.5
43.6
58.1
97.3
IGW4
BR4
43.7
68.4
43.7
65.2
61.3
43.3
47.8
48.9
90.8
51.8 52.6 51.2 59.3 57.0
4.4 3.5 3.9 5.9 5.3
Blood Volume, ml/kl_
Subject No.
4351
439
434
420
243
279
405
394
249
MEAN
SE
1GS2 1GS2
Ambulatory
Control BR4
56.7 53.7
44.8 43.0
35.4 35.7
39.0 38.6
51.8 53.2
53.9 45.9
52.4 47.1
49.9 45.4
1GW2 1GW2
Ambulatory
Control BR4
52.9 52.1
48.0 49.6
40.6 37.1
40.2 40.1
44.8 44.3
48.9 42.1
50.8 48.7
46.4 44.8
48.0 45.3 46.6 44.9
2.7 2.2 1.6 1.8
0(3, IGS4, 1GW4, IGS2, and IGW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Plasma AVP, pg/mi
0(3 1GS4 1GW4 1GW4
Subject No.
MEAN
SE
435
439
434
420i
243
279
405
394
249
0G
Ambulatory
Control BR4
0.95 1.55
0.95 1.15
1.80 2.15
2.20 2.85
1.40 1.40
3.20 2.55
0.65 0.50
6.65 3.05
2.30 2.50
2.23 1.97
0.61 0.29
IGS4
Ambulatory
Control BR4
1.10 1.60
1.30 1.65
1.70 1.40
1.95 1.65
1.25 0.90
2.55 2.30
0.85 0.75
4.35 3.45
1.65 2.25
1.86 1.77
0.35 0.27
Ambulatory
Control BR4
2.80 1.35
0.75 1.70
1.45 1.70
5.80 5.40
1.35 1.25
2.45 1.90
0.85 1.15
5.85 4.70
1.85 2.30
2.57 2.38
0.65 0.52
Plasma AVP, pg/ml
1GS2 1GW2 1GW2
Subject No.
435
439
434
420
243
279
405
394
249
1GS2
Ambulatory
Control BR4
1.55 1.05
1.10 1.05
1.05 1.20
2.85 2.20
1.15 2.05
0.70 0.95
3.10 2.15
2.10 1.80
Ambulatory
Control BR4
1.80 1.45
0.95 2.05
1.00 0.95
1.55 1.75
1.30 1.45
0.80 1.05
3.15 4.15
2.30 2.20
MEAN 1.70 1.56 1.61 1.88
SE 0.31 0.19 0.28 0.36
0G, IGS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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pg/ .....Plasma AVP, ml __,
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BR1 4-HR
0.70 1.00
0.47 0.37
1.07 1.17
1.10 1.30
0.95 1.20
1.20 1.10
0.73 0.43
1.33 2.00
2.57 1.73
1GS4 IGS4
Supine
Control BR1 4-HR
1.27 1.00
0.43 0.50
1.70 0.63
2.00 1.87
0.80 0.57
0.70 3.30
0.57 0.47
2.67 1.67
1.47 2.03
IGW4 IGW4
Supine
Control BRI 4-HR
1.07 0.67
0.53 0.60
0.80 0.93
2.70 1.50
1.10 0.53
1.57 2.80
0.40 0.50
3.30 3.07
2.23 2.80
MEAN 1.12 1.14 1.29 1.34 1.52 1.49
SE 0.20 0.18 0.25 0.32 0.34 0.37
0G, 1GS4, and 1GW4 denote respectively the no treatment and the 4 hr stand and 4 hr walk treatment conditions.
Supine Control values are from blood samples drawn on the ambulatory control day after subjects had been lying
quietly for 45 min (second samples drawn that day); BR1 4-HR values are from blood samples drawn 4 hr after
beginning HDBR on HDBR day 1. Plasma AVP (Supine Control and BRI 4-HR) data were not analyzed for the 2 hr
stand and 2 hr walk conditions.
51
Plasma Norepinephrine (NE), pg/ml
0G 1GS4 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
0G
Ambulatory
Control BR4
232 349
202 283
171 203
295 220
217 183
451 526
142 177
94 234
209 253
1GS4
Ambulatory
Control BR4
260 336
152
262 309
230 191
254 186
431 335
113 115
189 390
199 295
223.7 269.8
34.1 36.7
232.2 269.6
30.1 33.4
IGW4
Ambulatory
Control BR4
291 290
119 167
173 318
211 170
227 167
332 263
118 116
406 289
224 267
233.4 22%4
32.0 24.1
Plasma Norepinephrine (NE), p g/ml
1G S4 1GW4
435
439
434
420
243
279
405
394
249
Subject No.
0G 0G
Supine
Control BR1 4-HR
304 279
360 167
211 159
293 261
208 160
494 346
141 188
349 244
329 148
IGS4
Supine
Control BR1 4-HR
413 332
416 153
276 228
268 214
240 264
498 410
106 143
281 469
309 233
1GW4
Supine
Control BR1 4-HR
383 261
131 123
251 224
297 233
401 214
281 283
183 172
463 391
339 235
MEAN 298.8 216.9 311.9 271.8 303.2 237.3
SE 34.6 22.9 38.6 37.1 35.4 24.8
0G, 1GS4, and 1GW4 denote respectively the no treatment and the 4 hr stand and 4 hr walk treatment conditions.
Ambulatory Control values are from blood samples drawn on the ambulatory control day (first samples drawn that
day); BR4 values are from blood samples drawn on HDBR day 4. Supine Control values are from blood samples
drawn on the ambulatory control day after subjects had been lying quietly for 45 rain (Second samples drawn that
day); BRI 4-HR values are from blood samples drawn 4 hr after beginning HDBR on HDBR day 1. Plasma NE data
were not analyzed for the 2 hr stand and 2 hr walk conditions.
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Plasma Epinephrine (E), pg/ml
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Ambulatory
Control BR4
61 134
309 30
22 107
310 146
25 24
432 68
41 49
26 31
38 39
1GS4 1GS4
Ambulatory
Control BR4
40 53
587 136
22 107
109 53
107 17
224 45
115 46
51
182
1GW4 1GW4
Ambulatory
Control BR4
55 45
653 50
39 32
57 24
470 43
29 35
655
34 118
63 4645
MEAN 140.4 69.8 156.1 76.7 175.0 116.4
SE 53.9 15.8 65.5 17.8 86.2 67.9
Plasma Epinephrine (E), pg/ml
1GS4 IGW4
SubjectNo.
435 29
439 24
434 41
420 73
243 23
279 44
405 78
394 52
249 222
MEAN 69.8 65.1
SE 17.3 20.7
0G
Supine
Control
48
158
116
41
57
95
18
25
1GS4
Supine
Control BR1 4-HR
64 58
19 61
158 41
150 36
49 37
75 122
109 139
15
74 84
87.3 65.9
17.1 13.9
0G
BR1 4-HR
1GW4
Supine
Control BRI 4-HR
109 29
235 301
53 41
82
30 29
61 43
41 174
125
51 52
82.9 97.3
27.1 30.2
0G, 1GS4, and IGW4 denote respectively the no treatment and the 4 hr stand and 4 hr walk treatment conditions.
Ambulatory Control values are from blood samples drawn on the ambulatory control day (first samples drawn that
day); BR4 values are from samples drawn on HDBR day 4. Supine Control values are from blood samples drawn on
the ambulatory control day after subjects had been lying quietly for 45 min (second samples drawn that day); BR1
4-HR values are from blood samples drawn 4 hr after beginning HDBR on HDBR day 1. Plasma E data were not
analyzed for the 2 hr stand and 2 walk conditions.
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PRA, ng/mi/hr
0(3 1GS4 IGW4
Subject No.
435i
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
0.47 3.46
1.14 4.59
0.75 3.8I
0.80 0.57
0.48 1.25
1.16 1.46
0.18 0.66
0.18 0.97
0.32 2.98
1GS4
Ambulatory
Control BR4
0.22 1.72
2.35 1.28
0.61 1.84
1.02 0.44
0.46 0.63
1.37 0.99
0.55 0.39
0.09 0.86
0.13 1.22
1GW4
Ambulatory
Control
0.92
1.17
0.33
0.66
0.71
1.19
0.30
0.77
0.51
BR4
1.20
2.12
1.75
1.38
1.09
1.93
0.84
1.14
1.17
MEAN 0.61 2.19 0.76 1.04 0.73 1.40
SE 0.13 0.51 0.24 0.17 0.11 0.14
PRA, ng/ml/hr
Subject No.
435
439
434
420
243
279
405
394
249
IGS2 1GS2
Ambulatory
Control BR4
0.57 2.07
1.17 1.87
1.17 2.46
0.12 1.11
0.71 3.74
0.36 0.53
0.51 3.09
0.26 4.80
IGW2 1GW2
Ambulatory
Control BR4
1.14 0.34
0.60 3.23
0.71 2.05
0.62 0.93
0.44 1.89
0.26 0.82
0.32 1.38
0.32 1.01
MEAN 0.61 2.46 0.55 1.46
SE 0.14 0.49 0.10 0.32
0G, IGS4, 1GW4, 1GS2, and IGW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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PRA, ng/ml/hr
0G IGS4 IGW4
Subject No.
435
439
434
420
243
279
405
394
249
0(3
Supine
Control BRI 4-HR
0.74 0.26
1.04 0.60
0.87 1.75
0.90 0.36
0.68 0.54
1.04 1.05
0.01 0.20
0.29 0.18
0.22 0.28
1GS4
Supine
Control
0.56
2.15
1.39
0.65
0.58
2.01
0.24
0.33
0.30
BRI 4-HR
0.25
2.33
1.24
0.57
0.34
1.31
0.59
0.14
0.26
IGW4
Supine
Control
0.91
0.94
0.60
3.43
0.81
1.17
0.32
0.75
0.49
BR1 4-HR
0.40
0.87
1.47
0.86
! .30
1.36
0.12
0.68
0.66
MEAN 0.64 0.58 0.91 0.78 1.05 0.86
SE 0.13 0.17 0.25 0.24 0.31 0.15
PRA, ng/mi/hr
1GW2
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Supine
Control BR1 4-HR
1.15 0.23
1.22 1.03
0.88 0.90
0.51 0.51
0.74 0.61
0.18 0.16
0.61 0.71
0.80 0.42
IGW2
Supine
Control BR 1 4-HR
1.28 0.52
1.00 1.70
1.22 2.24
1.23 0.72
0.44 0.57
0.12 0.19
0.4 i 0.56
0.24 0.01
MEAN 0.76 0.57 0.74 0.81
SE 0.12 0.11 0.17 0.27
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 rain (second samples drawn that day); BRI 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
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Plasma Aldosterone, ng/dl
0G 1GS4 IGW4
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
13.0 45.2
6.0 35.7
7.9 35.3
20.9 20.6
12.4 12.3
22.4 21.6
6.0 11.6
5.8 8.4
13.9 31.4
12.0 24.7
2.1 4.3
1GS4
Ambulatory
Control BR4
15.8 21.7
27.5 9.4
11.4 18.9
14.4 14.2
14.1 8.6
39.0 19.9
6.4 6.2
4.8 17.6
14.6 30.8
16.4 16.4
3.6 2.6
IGW4
Ambulatory
Control
15.8
9.2
8.4
10.4
9.6
20.0
7.0
15.2
18.4
12.7
1.6
BR4
22.7
18.8
18.2
15.5
12.7
28.3
6.1
16.6
29.7
18.7
2.5
Plasma Aldosterone, ng/dl
IGS2 1GW2
Subject No.
435
439
434
420
243
279
405
394
249!
MEAN
SE
IGS2
Ambulatory
Control BR4
20.2 27.8
11.8 16.7
11.2 19.5
8.4 17.3
17.2 14.6
6.6 8.1
6.3 10.4
12.1 27.0
IGW2
Ambulatory
Control BR4
20.3 32.7
11.6 31.9
12.8 26.5
10.9 16.2
6.1 13.5
4.7 5.9
5.3 13.6
15.5 19.9
11.7 17.7 10.9 20.0
1.7 2.5 1.9 3.4
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn On the ambulatory control
day (first Samples-drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Plasma Aldosterone, ng]dl
"0G 1GS4 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Supine
Control BR1 4-HR
39.5 9.1
14.5 5.0
11.2 8.6
11.3 5.3
6.0 5.1
22.2 9.2
5.3 4.9
4.8 4.3
10.8 7.8
IGS4
Supine
Control BRI 4-HR
41.9 8.6
15.3 9.8
7.4 12.7
14.0 11.4
6.4 8.8
36.5 13.1
9.7 8.0
7.3 6.0
14.0 7.5
IGW4
Supine
Control
34.8
18.4
6.2
16.2
14.7
15.0
7.0
10.9
11.0
BR1 4-HR
11.4
7.6
8.4
11.5
9.8
12.3
7.1
7.8
7.4
MEAN 13.9 6.6 16.9 9.5 14.9 9.3
SE 3.7 0.7 4.4 0.8 2.8 0.7
Plasma Aldosterone, ng/dl
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Supine
Control BRI 4-HR
49.4 9.8
10.7 5.4
11.7 7.5
5.2 9.9
9.6 13.0
5.8 4.3
9.9 7.1
9.9 7.6
1GW2 IGW2
Supine
Control BR1 4-HR
48.3 10.4
18.0 5.7
20.0 7.9
26.3 15.8
5.9 7.3
6.4 5.3
5.1 10.8
8.5 8.3
MEAN 14.0 8.1 17.3 8.9
SE 5.1 1.0 5.2 1.2
0G, 1GS4, IGW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 min (second samples drawn that day); BRI 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
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Plasma Cortisol, lag/100 ml
0G 1GS4 1GW4
Subject No.
MEAN
SE
435
439
434
420
243i
279
405
394
249
0G
Ambulatory
Control BR4
17.9 16.0
17.2
19.2 27.0
23.5 20.9
21.8 18.8
15.4 18.1
15.6 17.1
12.0 14.2
18.1 17.3
17.9 18.5
1.3 1.2
1GS4
Ambulatory
Control BR4
17.9 18.7
18.3 17.9
20.2 23.2
18.1 21.1
18.0 20.2
21.0 17.7
17.2 14.5
10.1 13.6
19.6 21.2
17.8 18.7
1.1 1.1
1GW4
Ambulatory
Control
18.4
11.3
17.8
7.4
19.9
17.6
15.7
11.9
18.5
15.4
1.4
BR4
18.0
17.6
14.4
19.0
19.1
19.0
9.6
15.3
20.7
17.0
1.1
Plasma Cortisol, lag/100 ml
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
1GS2
Ambulatory
Control
21.3
17.2
19.1
15.2
22.7
1GS2
BR4
19.2
13.1
12.7
18.5
21.5
15.6 15.1
16.7 13.4
14.8 16.2
17.8 16.2
1.0 1.I
1GW2 1GW2
Ambulatory
Control BR4
20.6 18.4
15.7 17.6
21.1 19.4
14.4 16.5
15.2 15.4
12.5 7.2
14.1 14.6
17.2 16.8
16.4 15.7
1.1 1.3
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions, Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
58
Plasma Cortisol, I_g/lO0 mi |11
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BRI 4-HR
9.7 9.9
20.8 11.2
8.5 9.9
7.2 5.4
7.9 11.2
10.8 8.1
10.6 10.1
13.6 11.2
10.6 6.2
- .
1GS4 1GS4
Supine
Control BR1 4-HR
14.0 11.0
7.5 13.1
6.2 12.1
11.3 9.5
6.7 16.9
11.1 9.8
10.1 7.7
17.1 11.7
10.7 6.6
1GW4
Supine
Control
13.0
7.0
7.5
6.9
7.7
12.4
8.2
16.7
9.1
1GW4
BR1 4-HR
11.6
10.3
10.7
7.6
14.8
13.3
6.7
9.7
6.7
MEAN 11.1 9.2 10.5 10.9 9.8 10.2
SE 1.4 0.7 1.2 1.0 1.1 0.9
Plasma Cortisol, L__IO0 ml
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Supine
Control BR1 4-HR
13.3 12.1
4.4 6.2
7.1 7.1
6.6 9.1
13.4 18.1
11.0 7.9
11.8 14.0
11.3 7.3
1GW2 1GW2
Supine
Control BRI 4-HR
14.5 11.7
10.8 8.2
8.7 7.4
13.2 7.3
9.4 10.3
11.5 9.1
16.1 11,4
9.9 7.8
MEAN 9.9 10.2 11.8 9.2
SE 1.2 1.5 0.9 0.6
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 min (second samples drawn that day); BR1 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
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Plasma ANP, pg/mi
Subject No.
435
439
434
420
243
279
405!
394
249
0G
Ambulatory
Control
60.24
58.56
19.86
0G
BR4
14.28
23.01
2.69
1GS4 1GS4
Ambulatory
Control BR4
50.82 24.22
46.64 34.97
25.42 9.62
1GW4
Ambulatory
Control
36.15
28.76
24.76
45.84
6.93
40.94
31.24
60.14
25.84
36.24
4.95
11.55
6.17
19.53
26.87 48.07
41.32 47.77
23.53 10.86
43.18 18.93
19.07 14.58
64.26 33.72
56.08
20.14
36.73
11.57
59.65
1GW4
BR4
15.07
20.98
11.40
39.83
16.54
14.23
13.42
4.34
2.69
MEAN 40.47 16103 37.90 26.97 34.23 15.39
SE 7.03 3.70 5.02 4.96 5.92 3.60
Plasma ANP, pg/ml
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Ambulatory
Control BR4
33.73 48.68
56.02 24.54
21.65 13.82
31.19 23.97
32.57 14.97
38.33 19.76
12.03 10.22
34.77 5.50
1GW2 1GW2
Ambulatory
Control BR4
40.80 14.08
40.61 17.11
30.86 25.87
56.24 47.47
57.28 24.48
41.70 9.27
18.20 4.43
37.11 15.70
MEAN 32.54 20.18 40.35 19.80
SE 4.50 4.68 4.50 4.68
0G, 1GS4, 1GW4, 1GS2, and IGW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
60
Plasma ANP, pg/ml
0G IGS4 IGW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Supine
Control BR 1 4-HR
46.43 67.99
38.96 53.89
19.42 27.01
43.35 79.91
50.00
10.19 20.51
38.92 41.08
28.54 23.37
46.00 81.80
IGS4
Supine
Control BRI 4-HR
58.O3 62.68
30.72 50.77
44.48 36.42
47.61 66.85
38.84 47.29
7.00 9.63
32.28 39.14
18.49 16.52
48.39 37.45
IGW4
Supine
Control
72.04
26.86
18.86
42.04
43.36
24.27
29.74
17.71
48.93
BRI 4-HR
58.31
38.19
19.64
54.81
17.68
24.31
31.96
58.97
MEAN 35.76 49.45 36.20 40.75 35.98 37.98
SE 4.52 8.89 5.33 6.34 5.83 6.14
Plasma ANP, pg/mi
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Supine
Control BR1 4-HR
44.95 59.77
41.16 83.35
43.66 20.25
20.28 58.14
26.49 40.06
52.20 40.37
14.91 20.82
42.93 78.15
1GW2 IGW2
Supine
Control BR1 4-HR
40.49 20.40
41.63 39.57
36.87 22.36
63.69 61.46
51.76 67.91
34.83 36.52
28.08 18.57
38.23 52.13
4i.95 39.87
3.90 6.75
35.82 50.11
4.74 8.45
0G, IGS4, 1GW4, 1GS2, and IGW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 min (second samples drawn that day); BR1 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
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Plasma Sodium (Na), mEq/L
0(3 IGS4 IG_'4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
138.7 138.0
138.9 139.3
138.2 137.6
139.6 137.8
139.0 136.9
138.6 136.5
138.7 136.9
138.0 135.9
138.3 135.3
1GS4
Ambulatory
Control BR4
137.5 136.7
136.1 136.2
138.1 137.5
137.5 134.8
138.4 139.5
138.4 138.9
139.6 139.4
139.9 137.8
137.2 136.5
1GW4
Ambulatory
Control
136.8
137.6
139.4
138.2
136.4
138.1
139.1
139.0
137.8
BR4
135.5
138.3
138.3
140.4
135.4
136.1
138.9
137.7
138.4
MEAN 138.7 137.1 138.1 137.5 138.0 137.7
!SE 0.2 0.4 0.4 0.5 0.3 0.6
Plasma Sodium (Na), mEq/L
Subject No.
435
439
434
420
243
279
405
394
249
IGS2 IGS2
Ambulatory
Control BR4
130.1 132.1
133.7 134.8
135.2 131.3
131.0 132.7
132.4 132.0
134.9 133.8
131.6 128.5
131.4
1GW2 1GW2
Ambulatory
Control BR4
128.4 128.3
130.8 130.7
131.0 129.7
133.1 136.1
136.5 ! 32.2
130.9 129.7
135.4 131.4
132.1130.6 134.5
MEAN 132.5 132.0 132.6 131.3
SE 0.7 0.7 1.0 0.8
0G, IGS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Plasma Sodium (Na), mEq/L _ ;:_ 7
_, 0G 1GS4 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Supine
Control BR1 4-HR
140.3 138.4
138.3 137.9
138.0 139.1
139.9 136.1
138.4 135.0
137.3 134.7
139.1 131.0
137.6 129.8
137.1 130.3
IGS4
Supine
Control BR1 4-HR
136.8 138.1
138.3 135.8
139.7 135.2
132.4 136.9
139.0 137.2
137.9 138.0
140.4 140.2
139.0 130.2
134.1 138.3
IGW4
Supine
Control
136.7
137.1
139.0
139.5
131.3
134.8
138.3
140.2
138.0
BR1 4-HR
136.1
138.7
130.9
139.4
134.7
135.5
131.9
138,9
138.5
MEAN 138.4 134.7 137.5 136.7 137.2 136.1
SE 0.4 1.2 0.9 0.9 0.9 1.0
Plasma Sodium (Na), mEq/L
Subject No.
435
439
434
420
243
279
405
394
249 !
1GS2 1GS2
Supine
Control BRI 4-HR
132.6 133.7
133.2 134.6
135.4 129.8
132.4 132.1
131.8 129.8
178.4 131.3
131.4 127.5
132.1 131.6
1GW2 1GW2
Supine
Control BRI 4-HR
129.9 129.2
130.4 130.8
130.6 131.1
130.6 134.9
136.0 129.4
131.5 129.0
136.2 128.8
134.5 128.1
IMEAN 138.4 131.3 132.5 130.2
ISE 5.7 0.8 0.9 0.8
0(3, 1GS4, 1GW4, 1GS2, and IGW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 min (second samples drawn that day); BRI 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
63
Plasma Potassium (K), mEq/L
0(3 IGS4 IGW4
Subject No.
435
439
434i
420
243
279
405
394
249
0G
Ambulatory
Control BR4
4.07 4.41
4.12 4.26
4.41 4.35
4.34 4.24
4.20 4.08
4.25 4.36
4.22 4.42
3.79 3.71
4.31 4.43
BR4
4.43
3.95
4.55
3.91
3.96
4.17
4.04
3.71
4.31
1GS4
Ambulatory
Control
4.41
4.03
4.47
4.06
4.06
4.33
4.29
4.09
4.25
4.22
0.06
1GW4
Ambulatory
Control
4.07
4.13
4.52
4.25
4.05
3.96
4.45
3.79
4.15
BR4
4.43
4.02
4.53
3.96
3.81
3.94
4.18
3.57
4.13
MEAN 4.19 4.25 4.11 4.15 4.06
SE 0.06 0.08 0.09 0.08 0.10
Plasma Potassium (K), mEq/L
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Ambulatory
Control BR4
4.14 4.26
3.99 3.91
4.02 4.13
3.99 3.81
3.78 3.60
3.71 4.01
3.29 3.83
3.90 3.82
1GW2 1GW2
Ambulatory
Control BR4
4.28 3.83
3.77 3.87
3.96 4.10
3.92 4.00
3.94 3.81
4.03
3.58
4.10
3.95
0.07
3.95
3.87
3.87
MEAN 3.85 3.92 3.91
SE 0.09 0.07 0.03
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Plasma Potassium (K), mEq/L
IGW4
ISubject No.
435
439
434
42(
243
279
405
394
249
0G 0G
Supine
Control BR 1 4-HR
4.06 3.91
4.39 3.84
4.68 4.03
4.10 3.99
4.46 3.81
4.47 3.89
4.35 4.10
3.74 3.90
4.45 3.60
IGS4 IGS4
Supine
Control BRI 4-HR
4.09 4.62
4.04 3.75
4.47 3.99
3.86 3.96
4.35 4.01
4.26 4.21
4.28 5.11
4.06 4.30
4.68 4.01
1GW4
Supine
Control
3.81
4.45
4.29
3.75
4.08
4.02
4.54
3.83
4.41
BRI 4-HR
4.22
4.11
3.87
4.08
4.14
3.89
4.17
4.32
3.94
MEAN 4.30 3.90 4.23 4.22 4.13 4.08
SE 0.09 0.05 0.08 0.14 0.10 0.05
Plasma Potassium (K), mEq/L
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 IGS2
Supine
Control BRI 4-HR
3.97 3.96
4.05 3.87
4.08 3.66
3.91 3.83
3.80 4.21
4.85 3.92
3.70 3.97
3.89 3.67
1GW2 IGW2
Supine
Control BR1 4-HR
3.77 3.84
3.99 3.73
4.06 4.01
3.83 3.83
3.89 3.78
3.86 3.87
3.69 3.92
4.16 3.48
MEAN 4.03 3.89 3.91 3.81
SE 0.12 0.06 0.05 0.06
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 rain (second samples drawn that day); BR1 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
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Plasma Osmolallty, mOsm/kg
0(3 1GS4 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
281 283
284 288
282 284
288 287
281 285
283 284
287 288
286 285
285 286
IGS4
Ambulatory
Control BR4
282 285
292 293
288 293
290 290
284 285
285 288
283 287
287 287
281 283
1GW4
Ambulatory
Control
283
286
287
285
288
288
292
287
281
BR4
285
291
288
293
288
286
287
283
287
MEAN 284 286 286 288 286 288
SE 1 1 1 1 1 1
Plasma Osmolality, mOsm/kg
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 IGS2
Ambulatory
Control BR4
284 282
287 291
282 283
287 288
287 287
286 286
289 282
288 282
1GW2 1GW2
Ambulatory
Control BR4
287 282
287 291
287 287
288 291
285 283
285 283
283 283
285 281
MEAN 286 285 286 285
SE 1 1 1 1
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Plasma Osmolality, mOsm/kg _ :
0G 1GS4 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Supine
Control BR1 4-HR
285 286
282 286
283 285
286 288
284 283
282 284
290 290
287 287
286 288
1GS4
Supine
Control BR1 4-FIR
283 286
290 293
280 291
292 292
283 285
284 286
286 286
289 285
282 284
1GW4
Supine
Control
285
286
286
286
289
286
283
289
281
BR1 4-HR
287
289
287
288
287
288
288
285
286
MEAN 285 286 285 288 286 287
SE 1 1 1 1 1 0
Plasma Osmolality, mOsm/kg
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Supine
Control BR1 4-HR
285 284
288 288
284 288
291 284
285 287
286 289
289 285
287 283
IGW2 1GW2
Supine
Control BR1 4-HR
284 289
290 289
289 289
287 288
285 285
288 287
288 285
284 284
MEAN 287 286 287 287
SE 1 1 1 1
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 min (second samples drawn that day); BR1 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
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Serum Total Protein, g/dl
0(3 1GS4 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
7.5 7.5
7.5 7.8
8.3 8.5
7.3 7.8
7.3 8.0
7.3 8.3
1GS4
Ambulatory
Control BR4
7.5 8.0
7.8 8.0
7.8 8.0
7.5 8.0
1GW4
Ambulatory
Control
7.8
7.3
7.3
7.3
8.0
7.5
BR4
8.0
8.0
8.3
7.5
8.3
7.8
7.8 9.0
7.3 8.0
MEAN 7.5 8.0 7.6 8.2 7.5 8.0
SE 0.2 0.1 0.1 0.2 0.1 0.I
Serum Total Protein, g/dl
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
IGS2 1GS2
Ambulatory
Control BR4
8.0 8.2
7.8 8.0
7.4 8.1
7.4 7.4
7.4 7.4
7.1 7.8
7.5 8.0
7.5 8.0
7.5 7.9
0.1 0.1
1GW2 1GW2
Ambulatory
Control BR4
8.0 7.9
8.0 8.0
7.8 7.9
7.5 7.6
7.3 7.4
7.6 7.5
7.6 8.1
7.8 7.9
7.7 7.8
0.1 0.1
0G, IGS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4. Serum Total Protein
dam were not analyzed for the first HDBR exposure.
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,i
Serum Total Protein, g/dl
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BR 1 4-HR
°
7.5 7.5
7.3 7.5
8.3 8.3
7.5 7.8
7.3 7.3
7.8 7.5
1GS4 IGS4
Supine
Control BR1 4-HR
7.8 8.3
8.0 8.0
7.8 8.0
7.8 7.8
1GW4
Supine
Control
7.8 7.8
7.5 8.0
7.8
7.5
7.8
7.5
8.3
7.5
1GW4
BR1 4-HR
7.8
7.8
7.5
7.8
8.3
7.8
MEAN 7.6 7.7 7.8 8.0 7.7 7.8
SE 0.2 0.1 0.1 0.1 0.1 0.1
Serum Total Protein, g/dl
Subject No.
435
439
434
420
243
279
405
394
249
IGS2 IGS2
Supine
Control BR1 4-HR
8.2 8.1
7.9 7.9
7.8 7.6
7.6 7.4
7.2 7.6
7.3 7.6
7.9 8.0
7.9 7.5
1GW2 1GW2
Supine
Control BR1 4-HR
8.2 8.0
8.0 8.2
7.9 8.1
7.6 7.5
7.4 7.6
7.8 7.9
7.7 7.8
7.8 7.8
MEAN 7.7 7.7 7.8 7.9
SE 0.1 0.1 0.1 0.1
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 rain (second samples drawn that day); BR1 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day I. Serum Total Protein data were not analyzed for the
first HDBR exposure.
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Plasma Total Cholesterol, mg/dl
0(3 1GW4
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control
176
143
220
275
182
197
168
142
167
186
14
BR4
172
136
254
271
223
213
180
169
206
203
14
1GW4
Ambulatory
Control BR4
169 181
152 155
230 239
264 275
197 225
196 209
194 194
145 159
170 196
191 204
13 13
Plasma Total Cholesterol, mg/dl
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
0G 0G
Supine
Control BR1 4-HR
170 177
145 143
232 245
277 279
183 194
202 200
181 191
146 149
177 183
190 196
14 14
IGW4 IGW4
Supine
Control BR1 4-HR
177 179
156 160
253 239
271 285
199 209
196 199
205 199
148 152
173 171
198 199
14 14
0G andlGW4 denote respectively the no treatment and the 4 hr walk treatment
conditions. Ambulatory Control values are from blood samples drawn on the
ambulatory control day (first samples drawn that day); BR4 values are from blood
samples drawn on HDBR day 4. Supine Control values are from blood samples
drawn on the ambulatory control day after subjects had been lying quietly for 45
min (second samples drawn that day); BR1 4-HR values are from blood samples
drawn 4 hr after beginning HDBR on HDBR day 1.
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Plasma HDL Cholesterol, mg/dl _._.___
0(3 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
51 43
31 27
21 24
37 39
48 47
26 27
40 31
62 64
39 41
IGW_I
Ambulatory
Control BR4
63 54
27 27
27 25
39 38
46 48
24 27
39 26
60 56
41 47
MEAN 39 38 41 39
SE 4 4 5 4
Plasma HDL Cholesterol, mg/dl
1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BR1 4-HR
51 48
31 28
22 21
38 37
50 47
27 27
40 37
63 62
40 37
1GW4
Supine
Control BR1 4-HR
65 57
28 27
28 24
40 37
47 46
24 23
42 37
60 57
42 37
MEAN 40 38 42 38
SE 4 4 5 4
0G andlGW4 denote respectively the no treatment and the 4 hr walk treatment
conditions. Ambulatory Control values are from blood samples drawn on the
ambulatory control day (first samples drawn that day); BR4 values are from blood
samples drawn on HDBR day 4. Supine Control values are from blood samples
drawn on the ambulatory control day after subjects had been lying quietly for 45
min (second samples drawn that day); BRI 4-HR values are from blood samples
drawn 4 hr after beginning HDBR on HDBR day 1.
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Plasma LDL Cholesterol, mg/dl
0G 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
0G
Ambulatory
Control BR4
106 105
80 75
136 160
201 202
121 167
140 155
106 111
67 89
113 151
119 135
13 14
IGW4
Ambulatory
Control BR4
91 i10
83 91
151 167
178 210
142 166
136 157
135 143
76 92
117 138
123 i42
11 13
Plasma LDL Cholesterol, mg/dl
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BR1 4-HR
97 96
86 77
143 105
194 189
120 125
143 131
117 114
68 71
118 121
iGW4 1GW4
Supine
Control BR1 4-HR
92 93
83 73
155 129
179 181
142 147
133 129
142 118
78 84
115 108
MEAN 121 114 124 118
SE 12 12 12 11
0G andlGW4 denote respectively the no treatment and the 4 hr walk treatment
conditions. Ambulatory Control values are from blood samples drawn on the
ambulatory control day (first samples drawn that day); BR4 values are from blood
samples drawn on HDBR day 4. Supine Control values are from blood samples
drawn on the ambulatory control day after subjects had been lying quiedy for 45
min (second samples drawn that day); BR1 4-HR values are from blood samples
drawn 4 hr after beginning HDBR on HDBR day 1. Plasma LDL cholesterol values
were calculated using the formula: Plasma LDL cholesterol = Plasma total
cholesterol - [Plasma HDH cholesterol + (Plasma triglycerides/5)].
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Plasma Triglycerides, mg/dl
OG 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
96 119
159 169
316 351
183 150
65 47
153 154
I10 188
63 78
76 71
1GW4
Ambulatory
Control BR4
77 85
208 185
262 233
235 134
45 56
179 126
102 123
44 55
62 57
MEAN 136 147 135 117
SE 27 30 29 21
P_sma Triglycerides, mg/di
1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BRI 4-HR
112 163
138 192
333 594
224 263
66 110
160 211
121 202
75 80
93 127
IGW4
Supine
Control BR 1 4-HR
101 143
225 302
350 432
262 335
51 79
195 237
107 222
51 56
79 131
MEAN 147 216 158 215
SE 28 51 35 42
0G andlGW4 denote respectively the no treatment and the 4 hr walk treatment
conditions. Ambulatory Control values are from blood samples drawn on the
ambulatory control day (first samples drawn that day); BR4 values are from blood
samples drawn on HDBR day 4. Supine Control values are from blood samples
drawn on the ambulatory control day after subjects had been lying quietly for 45
rain (second samples drawn that day); BRI 4-HR values are from blood samples
drawn 4 hr after beginning HDBR on HDBR day 1.
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Serum Creatinine, m_dl
0(3 IGS4 1GW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control
0.9
1.0
1.0
1.0
0.9
0.9
1.1
1.1
1.1
BR4
0.9
0.9
1.2
1.0
1.0
0.9
1.1
1.2
1.1
1GS4
Ambulatory
Control BR4
0.8 0.8
0.9 1.0
1.1 1.1
1.1 1.1
1.0 1.0
1.0 0.9
1.0 1.1
1.1 1.1
0.9 1.0
1GW4
Ambulatory
Control
0.9
0.9
1.1
1.0
1.0
0.9
1.1
1.1
1.0
BR4
0.8
0.9
1.1
0.9
1.0
1.1
1.1
1.1
1.0
MEAN 1.0 1.0 1.0 1.0 1.0 1.0
SE 0.0 0.0 0.0 0.0 0.0 0.0
Serum Creatinine, mg/dl
Subject No.
435
439
434
420
243
1GS2
Ambulatory
Control
0.8
1.0
1.1
1.0
1.0
279
405 1.1
394 1.0
249 1.1
1.0
0.0
1GS2
BR4
0.9
1.1
1.1
t.0
1.0
1.1
1.2
1.1
1.1
0.0
1GW2 IGW2
Ambulatory
Control BR4
0.8 0.9
0.9 1.0
1.1 1.2
1.0 1.1
1.0 1.0
1.0 1.0
1.1 1.1
1.0 1.0
1.0 1.0
0.0 0.0
0G, 1GS4, IGW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Ambulatory Control values are from blood samples drawn on the ambulatory control
day (first samples drawn that day); BR4 values are from blood samples drawn on HDBR day 4.
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Serum Creatinine, mg/dl _ _ : .___ '
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BRI 4-HR
0.9 0.8
1.1 1.0
0.9 1.0
1.0 1.0
0.9 1.0
0.9 1.0
1.1 1.0
1.1 1.1
1.0 1.1
IGS4 IGS4
Supine
Control BR 1 4-HR
0.8 0.8
1.0 0.9
1.0 1.1
1.2 1.1
0.9 1.0
1.0 1.0
1.0 1.0
1.1 1.1
1.0 1.0
1GW4
Supine
Control
0.9
0.9
1.0
1.1
1.0
0.9
1.1
1.1
1.0
,
IGW4
BR1 4-HR
0.9
0.9
1.I
1.0
1.1
1.0
1.1
1.0
1.1
MEAN 1.0 1.0 1.0 1.0 1.0 1.0
SE 0.0 0.0 0.0 0.0 0.0 0.0
Serum Creatinine, mg/dl
 6s2  GS2 1GW2 IGW2
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
Supine
Control
0.9
1.1
1.1
1.0
1.0
1.1
1.I
1.0
BR1 4-HR
Supine
Control BRI 4-HR
0.9
0.9
1.2
1.1
1.0
0.8 0.9
1.0 0.9
1.1 1.0
1.0 1.0
1.0 1.0
1.1 1.0
1.0 1.1
1.0 1.0
1.0
0.0
1.0
1.1
1.0
1.0 1.0 1.0
SE 0.0 0.0 0.0
0G, 1GS4, IGW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. Supine Control values are from blood samples drawn on the ambulatory control day
after subjects had been lying quietly for 45 min (second samples drawn that day); BRI 4-HR values are from blood
samples drawn 4 hr after beginning HDBR on HDBR day 1.
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UrinaryCreatinine, rag/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G 0G
C1 BR1 BR2 BR3 BR4
1986 2035 1887 1838 1926
2023 2365 2134 2535 2228
2456 2698 1705 3331 2418
2053 2120 2094 2040 2030
2252 2284 2279 2157 2234
2432 2124 2412 2306 2136
2606 1654 4009 2169 2365
2061 2278 2209 2354 2246
2075 1697 1249 2591 1330
MEAN 2216 2139 2220 2369 2101
SE 76 108 252 143 109
Urinary Creatinine, mg/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GS4 1GS4 1GS4 IGS4 1GS4
C1 BRI BR2 BR3 BR4
1907 1728 1799 2007 1460
2339 2113 2193 2295 2412
1954 2506 2345 2298 2484
2219 2027 2028 2217 2112
1976 2548 2564 2537 2273
2109 2119 2146 2426 2542
2138 1897 2480 4008 2738
1711 2283 2330 2369 2577
2031 2091 2119 1969 1784
MEAN 2043 2146 2223 2458 2265
SE 62 89 79 203 138
Urinary Creatinine, rag/24 hr
1GW4
Subject No.
435
439
434
420
243 2204
279 2002
405 2207
394 2576
249 2497
MEAN 2037
SE 138
1GW4
C1 BRI
1309 2459
2094 2235
1520 2363
1925 2209
1GW4 1GW4 1GW4
BR2 BR3 BR4
2085 1997 1456
2276 2066 2053
2497 1689 2299
2241 2400 2035
2359 2316 2355
2540 2124 2399
1955 2267 2629
2376 2385 2659
1091 3416 1442
2265
2381
2703
2172
2349
2348 2158 2296 2147
54 147 159 150
0G, IGS4, and 1GW4 denote respectively the no treatment condition and the 4 hr stand and 4 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Urinary Creatinine, mg/24_hr ,,,
IGS2 IGS2 1GS2 1GS2
Subject No.
435
439
434
420
243
279
405
394
249
IGS2
C1 BR1 BR2 BR3 BR4
2075-- 1534 2132 2045 1707
2582 1934 2827 1778 1981
3000 2142 2538 2396 2346
2875 1867 2023 2064 2090
1721 2265 2225 2184 2212
2160 2081 1778 2707 2430
2911 2214 2221 2091 2292
2516 2360 1949 2136 2197
MEAN 2480 2050 2212 2175 2157
SE 162 94 118 97 81
Urinary Creatinine, m_24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 IGW2 IGW2 1GW2 IGW2
C1 BR1 BR2 BR3 BR4
1960 1339 2115 2069 1812
2420 2367 2119 2653 2252
2467 2656 2362 2532 2443
2073 1610 2463 2141 2283
2190 2271 2159 1924 2425
2286 2476 2388 2093 2391
2750 2019 2389 2181 2330
2026 2035 2001 2049 2107
MEAN 2272 2097 2250 2205 2255
SE 94 157 60 89 74
1GS2 and 1GW2 denote respectively the 2 hr sland and 2 hr walk treatment conditions. C1, BR1,
B1L2, BR3, and BR4 denote ambulatory control and HDBR days.
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Glomerular Filtration Rate (GFR), dl/min
0(3 1GS4 IGW4
Subject No.
435
439
434
420
243
279
405
394
249
0G
Ambulatory
Control BR4
1.532 1.486
1.405 1.719
1.706 1.399
1.426 1.410
1.738 1.551
1.877 1.648
1.645 1.493
1.301 1.300
1.310 0.840
1GS4
Ambulatory
Control BR4
1.655 1.267
1.805 1.675
1.234 1.568
1.401 1.333
1.372 1.578
1.465 1.961
1.485 1.729
1.080 1.627
1.567 1.239
1GW4
Ambulatory
Control
1.010
1.616
0.960
1.337
1.531
1.545
1.393
1.626
1.734
BR4
1.264
1.584
1.451
1.570
1.635
1.515
1.660
1.679
1.001
!MEAN 1.549 1.427 1.452 1.553 1.417 1.484
SE 0.068 0.085 0.072 0.079 0.091 0.074
Glomerular Filtration Rate (GFR), dl/min
Subject No.
MEAN
!SE
435
439
434
420
243
279
405
394
249!
1GS2 IGS2
Ambulatory
Control BR4
1.801 1.317
1.793 1.251
1.894 1.481
1.997 1.451
1.195 1.536
1.364 1.534
2.022 1.326
1.588 1.387
1.707 1.410
0.106 0.038
1GW2 1GW2
Ambulatory
Control BR4
1.701 1.398
1.867 1.564
1.557 1.414
1.440 1.441
1.521 1.684
1.588 1.660
1.736 1.471
1.407 1.463
1.602 1.512
0.055 0.039
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. GFR values were calculated using the formula: GFR = (Urinary creatinine excretion
rate/Serum creatinine)/1440. Ambulatory Control values were calculated using urinary creatinine data from the
ambulatory control day and serum creatinine data from blood samples drawn on the ambulatory control day (first
samples drawn that day). BR4 values were calculated using urinary creatinine data from HDBR day 4 and serum
creatinine data from blood samples drawn on HDBR day 4.
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Giomerular Filtration Rate (GFR), dl/min
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G
Supine
Control BR1 4-HR
1.532 1.766
1.277 1.642
1.895 1.874
1.426 1.472
1.738 1.586
1.877 1.475
1.645 1.149
1.301 1.438
1.441 1.071
" • i|l
1GS4 IGS4
Supine
Control BR1 4-HR
1.655 1.500
1.624 1.630
1.357 1.582
1.284 1.280
1.525 1.769
1.465 1.472
1.485 1.317
1.080 1.44 1
1.410 1.452
1GW4
Supine
Control
1.010
1.616
1.056
1.215
1.531
1.545
1.393
1.626
1.734
1GW4
BR1 4-HR
1.897
1.725
1.492
1.534
1.430
1.653
1.706
1.508
1.483
MEAN 1.570 1.497 1.432 1.494 1.414 1.603
SE 0.077 0.087 0.059 0.051 0.087 0.051
Glomerular Filtration Rate (GFR), di/min
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2
Supine
Control BR1 4-HR
1.601 1.332
1.630 1.343
1.894 1.352
1.997 1.297
1.195 1.573
1.364 1.314
1.838 1.538
1.747 1.639
1GW2 1GW2
Supine
Control BR1 4-HR
1.512 1.033
1.867 1.826
1.713 1.537
1.440 1.016
1.521 1.577
1.588 1.719
1.736 1.275
1.407 1.413
MEAN 1.658 1.424 1.598 1.425
SE 0.096 0.048 0.057 0.106
0G, 1GS4, 1GW4, 1GS2, and 1GW2 denote respectively the no treatment and the 4 hr stand, 4 hr walk, 2 hr stand, and
2 hr walk treatment conditions. GFR values were calculated using the formula: GFR = (Urinary creatinine excretion
rate/Serum creatinine)/1440. Supine Control values were calculated using urinary creatinine data from the ambulatory
control day and serum creatinine data from blood samples drawn on the ambulatory control day after subjects had been
lying quietly for 45 min (second samples drawn that day); BRI 4-HR values were calculated using urinary creatinine
data from HDBR day 1 and serum creatinine data from blood samples drawn 4 hr after beginning HDBR on HDBR
day 1.
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Urinary Osmolality,mOsm/kg
O(3
SubjectNo. CI
435 547
439 326
434i 396
420 579
243 730
279 509
405 484
394 685
249 590
MEAN 538
SE 43
0G 0G 0G 0G
BR1 BR2 BR3 BR4
567 539 547 707
457 798 836 862
596 686 896 705
851 935 1011 762
665 594 708 619
505 755 791 590
471 509 584 451
683 900 1015 1012
574 662 713 809
597 709 789 724
41 50 56 55
Urinary Osmolality, mOsm/kg
1GS4
Subject No. C 1
435 432
439 782
434 554
420 960
243 501
279 528
405 531
394 950
249 542
MEAN 642
SE 67
iGS4 1GS4 IGS4 IGS4
BRI BR2 BR3 BR4
493 532 650 560
825 871 873 880
932 873 950 879
910 940 904 902
563 544 597 518
583 563 474 711
550 547 587 496
916 976 998 1026
644 492 669 701
713 704 745 741
60 68 63 64
Urinary Osmolality' mOsm/kg
1GW4
Subject No. C1
435 385
439 487
434 622
420 661
243 588
279 400
405 416
394 996
249 621
MEAN 575"
SE 63
IGW4 1GW4 IGW4 IGW4
BR1 BR2 BR3 BR4
696 969 848 688
715 890 934 931
789 950 1048 966
851 1038 1067 1066
600 738 656 900
765 714 528 987
739 793 867 671
946 1015 1069 1026
794 936 955 958
766 894 886 910
33 40 63 47
0(3, IGS4, and IGW4 denote respectively the no treatment condition and the 4 hr stand and 4 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Urinary Osmolality, mOsm/kg
Subject No.
435
439
434
420
243
279
405
394
249
IGS2 IGS2 IGS2 IGS2 IGS2
C1 BRI BR2 BR3 BR4
414 421 454 558 444
635 637 732 703 783
514 546 474 577 562
517 447 783 671 630
341 329 449 427 795
405 379 472 493 427
904 642 643 665 851
686 507 632 507 738
MEAN 552 489 580 575 654
SE 65 41 48 35 58
Urinary Osmolality, mOsm/kg
1GW2 IGW2
Subject No. CI
435 318
439 520
434 515
420 607
243 437
279
405 481
394 753
249 559
IMEAN 524 616 698 702 784
SE 45 57 46 68 66
Urinary Cortisol, lag/24hr
1GW2 1GW2 IGW2
BRI BR2 BR3 BR4
515 510 760 507
726 856 914 891
834 600 606 902
763 706 869 976
437 546 392 778
423 772 469 516
712 795 859 954
517 797 750 749
Subject No.
435
439
434
420
243]
279
405
394
249
0G 0G 0G 0G 0G
CI BR1 BR2 BR3 BR4
54.3 65.9 63.6 64.2 58.9
55.4 70.2 49.1 48.8 60.7
51.0 44.0 25.2 45. I 40.0
37.2 47.4 46.1 48.2 46.8
59.1 60.6 64.8 50.9 87.6
109.2 73.1 79.2 102.3 74.9
91.8 50.7 67.0 54.6 98.9
48.3 84. I 74.6 61.9 60. I
57.0 40.0 29.8 47.9 35.6
MEAN 62.6 59.6 55.5 58.2 62.6
SE 7.6 5.0 6.4 5.9 7.1
0G, 1GS2, and 1GW2 denote respectively the no treatment condition and the 2 hr stand and 2 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Urinary,Cortisol, gg/24 hr
1GS4
_Subject No. C 1
435 59.3
439 39.7
434 25.5
420 58.9
243 44.0
279 64.2
405 43.1
394 41.3
249 53.4
1GS4 1GS4 1GS4 1GS4
BR1 BR2 BR3 BR4
49.4 67.4 76.8 54.2
34.9 43.3 45.0 49.3
37.7 33.2 42.0 39.4
46.3 39.5 80.4 47.1
69.0 95.3 86.8 68.1
79.7 67.9 90.9 91.9
56.8 57.8 71.7 54.4
57.8 50.4 74.6 62,5
50.3 90.2 35.7 50.0
MEAN 47.7 53.5 60.6 67.1 57.4
SE 4.1 4.8 7.3 6.9 5.1
Urinary Cortisol, lag/24 hr
Subject No.
435
439
434
420
243i
279
405
394
249
1GW4 1GW4 1GW4 1GW4 I GW4
C 1 BR1 BR2 BR3 BR4
41.1 80.5 66.7 84.6 61.4
37.6 32.7 39.9 36.9 45.8
25.0 20.2 21.5 15.8 29.5
35.5 31.0 29.7 37.5 46.9
55.6 68.3 63.5 60.3 63.8
61.7 68.2 82.2 56.0 97.3
41.5 66.8 20.2 37.8 76.7
68.6 57.0 60.2 59.9 77.9
47.5 51.5 21.5 53.2 30.6
MEAN 46.0 52.9 45.0 49.1 58.9
SE 4.6 6.9 7.8 6.5 7.6
Urinary Cortisol, lag]24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 IGS2 1GS2 1GS2 1GS2
C 1 BR 1 BR2 BR3 BR4
65.5 43.9 65.2 78.3 44.4
34.6 29.3 45.2 16.7 28.6
42.9 24.5 44.9 40.5 34.5
46.5 38.3 31.6 37.8 41.9
79.6 92.9 89.5 89.9 60.0
51.4 60.3 25.2 57.0 58.4
54.4 47.0 54.1 47.5 51.7
46.1 50.2 26.6 35.5 41.0
MEAN 52.6 48.3 47.8 50.4 45.1
SE 5.0 7.5 7.7 8.5 3.9
1GS4, 1GW4, and 1GS2 denote respectively the 4 hr stand, 4 hr walk, and 2 hr stand treatment
conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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UrinaryCortisol, lag/24 hr" '
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 1GW2 1GW2 1GW2 1GW2
CI BR1 BR2 BR3 BR4
69.5 36.9 55.5 65.0 68.1
32.2 28.2 27.6 33.8 35.7
42.4 40.4 38.0 39.5 43.1
33.5 19.1 36.6 32.4 40.8
71.1 47.8 46.8 45.3 41.9
50.2 52.2 39.1 46.8 42.7
67.3 40.1 61.2 42.3 48.3
51.3 31.7 26.6 30.4 39.1
MEAN 52.2 37.1 41.4 41.9 45.0
SE 5.6 3.8 4.4 3.9 3.5
Urinary Calcium (Ca), mg/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G 0G
C 1 BR 1 BR2 BR3 BR4
108.5 259.3 267.5 296.8 313.0
48.0 145.9 135.5 171.1 86.4
56.3 120.8 126.5 106.2 141.6
185.8 232.3 320.6 267.6 267.6
220.0 287.1 324.0 294.8 292.0
63.2 93.8 138.3 149.6 144.0
195.3 165.4 264.6 200.4 223.3
140.4 251.4 250.8 204.2 223.8
201.0 255.7 228.0 344.4 190.6
MEAN 135.4 201.3 228.4 226.1 209.1
SE 22.8 23.4 25.9 26.3 25.2
Urinary Calcium (Ca), mg/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GS4 1GS4 1GS4 1GS4 IGS4
C 1 BR 1 BR2 BR3 BR4
351.5 197.7 297.5 326.6 240.8
173.3 220.0 212.9 280.5 291.3
82.0 159.0 148.2 157.1 111.0
183.6 258.9 248.0 319.1 285.6
220.8 305.3 323.8 286.9 254.8
85.2 154.8 163.3 148.7 136.6
115.5 197.0 172.4 203.3 203.0
153.0 177.8 181.3 276.9 211.7
233.8 266.4 313.6 242.3 238.2
MEAN 177.6 215.2 229.0 249.0 219.2
SE 28.2 17.3 22.9 22.0 20.6
0G, 1GS4, and IGW2 denote respectively the no treatment condition and the 4 hr stand and 2 hr walk
treatment conditions. C 1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Urinary Calcium (Ca), mg/24 hr
1cw4 IGW4
Subject No. C 1 BR4
435 223.2
439 130.8 197.6
434 107.1 115.7
420 187.5 250.5
243 264.0 244.8
279 271.2 114.4
405 195.1 207.7
394 139.1 223.0
249 276.0 178.6
1GW4 1GW4 1GW4
BR1 BR2 BR3
300.8 133.4 339.8
196.1 181.2 168.6
85.2 107.3 102.8
205.2 226.3 357.3
297.5 262.8 304.0
163.7 135.0 128.9
179.3 159.2 189.2
171.0 216.9 227.0
267.3 129.6 409.5
MEAN 199.3 207.3 172.4 247.5 191.5
SE 21.3 23.4 17.6 36.3 18.6
Urinary Calcium (Ca), mg/24 hr
Subject No.
435
439
434
420
243
279
405
394
249_
1GS2 IGS2 1GS2 1GS2 1GS2
C 1 BR 1 BR2 BR3 BR4
143.4 59.3 279.6 327.8 282.8
124.7 146.5 180.8 135.7 163.2
166.8 122.4 141.9 158.6 135.2
222.5 322.2 257.1 308.0 306.9
222.0 361.2 357.8 376.2 199.9
146.9 246.8 157.2 211.0 243.5
308.7 235.2 254.7 266.9 253.5
273.3 365.1 308.4 334.4 289.2
MEAN 201.0 232.3 242.2 264.8 234.3
SE 23.5 40.5 26.9 31.0 22.0
Urinary Calcium (Ca), mg/24 hr _,
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 1GW2 1GW2 1GW2 1GW2
C1 BR1 BR2 BR3 BR4
222.4 42.8 288.0 288.7 264.7
141.1 141.2 138.2 157.5 157.7
141.2 123.3 136.7 152.1 125.7
232.2 140.7 322.3 263.1 278.6
263.5 208.0 193.8 267.8 266.6
201.0 192.2 151.4 183.2 195.7
276.0 177.0 229.5 232.5 228.3
222.3 279.8 177.4 278.3 302.4
MEAN 212.5 163.1 204.7 227.9 227.5
SE 17.7 24.5 24.7 19.7 22.1
1GW4, IGS2, and 1GW2 denote respectively the 4 hr walk, 2 hr stand, and 2 hr walk treatment
conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Sodium (Na) Intake, mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G 0G
C1 BR1 BR2 BR3 BR4
185.5 186.1 172.4 198.7 173.4
186.0 185.9 172.1 198.8 166.4
185.1 185.8 171.5 181.4 165.5
163.9 171.7 166.9 193.5 172.9
185.4 185.6 172.0 198.2 172.9
122.0 163.3 162.5 162.0 148.0
185.5 185.9 172.4 198.5 173.3
161.6 185.0 171.5 197.9 ! 73.0
184.9 185.4 171.8 197.9 173.3
MEAN 173.3 181.6 170.3 191.9 168.7
SE 7.2 2.8 1,1 4.2 2.8
Sodium (Na) Intake, mEq/24.hr
Subject No.
435
439
434
420
243
279
405
394!
2491
IGS4 1GS4 1GS4 1GS4 1GS4
C 1 BR 1 BR2 BR3 BR4
176.2 172.5 198.7 186.7 168.8
176.4 173.0 199.0 186.9 168.5
167.6 200.8 185.0 171.1 184.0
161.8 169.3 198.0 186.1 157.5
167.9 201.6 185.6 171.8 188.2
173.8 171.9 183.6 169.4 147.0
175.8 ] 72.4 198.4 186.5 168.9
167.9 168.6 184.9 171.3 187.7
175.8 111.5 198.1 186.1 168.2
MEAN 171.5 171.3 192.4 179.5' 171.0
SE 1.8 8.6 2.4 2.7 4.6
Sodium (Na) Intake, mEq/24 hr
1GW4
Subject No.
435
439
434
420
243
279
405
394
249
1GW4 1GW4 1GW4 1GW4
CI BRI BR2 BR3 BR4
168.8 199.6 185.9 172.4 188.7
176.4 172.5 198.9 186.4 168.5
168.1 201.2 185.0 171.6 184.7
168.3 197.1 171.7 171.8 187.7
175.7 171.5 197.9 186.3 167.9
168,6 204.1 165.9 171.5 174.1
168.5 202.1 186.1 172.2 188.8
158.3 167.3 198. I 169. I 167.9
167.9 184.9 185.6 168.6 188.7
r_
MEAN I69.0 I88.9 I86.1 I74.4 179.7
SE 1.7 5.0 3.8 2.3 3.3
0G, 1GS4, and IGW4 denote respectively the no treatment condition and the 4 hr stand and 4 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory and HDBR days.
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Sodium (Na) Intake, mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
MEAN
SE
IGS2 1GS2 1GS2 1GS2 1GS2
CI BR1 BR2 BR3 BR4
161.9 196,4 165.9 185.9 167.7
161.9 199.7 162.8 185.9 166.9
104.9 150.5 227.8 162.6 175.5
171.9 165.6 171.2 166.3 146.2
151.6 199.2 199.4 151.3 175.7
183.4 165.9 186.0 180.7 152.1
151,2 196.1 203.0 162.6 148.0
182.8 162.6 185.4 170.3 151.6
158.7 179.5 187.7 170.7 160.5
8.9 7.1 7.7 4.4 4.3
Sodium (Na) Intake, mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 1GW2 1GW2 1GW2 1GW2
C1 BRI BR2 BR3 BR4
205.6 200.0 165.9 185.9 167.7
205.6 199.4 165.9 186.0 166.9
202.3 199.1 153.3 i85.2 165.8
161.7 183.7 165.6 171.1 162.6
143.3 157.5 199.4 165.6 175.7
152.2 199.5 199.7 162.8 175.9
142.9 148.4 168.0 162.6 167.5
182.8 153.3 158.4 180.4 151.6
MEAN 174.6 180.1 172.0 175.0 166.7
SE 9.8 8.2 6.2 3.7 2.7
Urinary Sodium (Na), mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G 0G
C 1 BR 1 BR2 BR3 BR4
167.7 196.7 229.7 176.4 127.8
81.6 163.4 138.7 139.6 87.5
163.0 173.5 162.7 149.2 92.6
153.5 152.8 163.4 150.8 117.2
174.8 220.9 143.4 147.7 95.0
137.3 189.0 143.8 160.5 113.3
265.6 196.7 192.7 158.5 157.2
128.8 283.7 162.0 136.3 120.2
198.8 221.6 168.6 200.7 87.8
MEAN 163.5 199.8 167.2 157.7 111.0
SE 16.9 13.1 9.5 6.7 7.7
0G, 1GS2, and 1Gw2 denote respectively the no treatmentcondition and the 2 hr stand and 2 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Urinar.y ISodium (Na), mEqi24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GS4 1GS4 IGS4 IGS4 IGS4
C 1 BR1 BR2 BR3 BR4
167.6 193.7 213.8 162.0 137.3
105.7 135.5 171.4 192.0 186.0
166.8 173.0 166.9 159.2 142.4
79.9 101.7 155.3 192.4 132.5
85.4 160.8 160.1 159.8 142.1
62.9 138.1 155.6 160.1 125.5
105.3 164.4 178.9 180.5 164.8
142.2 199.5 159.5 156.2 147.6
181.9 189.0 165.6 145.1 116.7
MEAN 122.0 161.7 169.7 167.5 143.9
SE 14.5 10.7 6.1 5.6 7.0
Urinary Sodium (Na), mEx]/24 hr
Subject No.
1GW4 ] GW4 1GW4 1GW4 1GW4
C 1 BR 1 BR2 BR3 BR4
118.3 279.4 171.4 161.9 167.4
124.6 175.7 198.8 142.4 145.3
167.4 145.7 159.7 99.3 154.4
90.1 131.3 123.7 159.4 119.7
137.0 190.1 176.5 131.9 107.3
145.5 137.2 160.4 133.0 142.3
142.7 219.6 151.0 127.9 170.8
80.5 177.6 131.2 105.6 137.4
179.4 217.1 68.1 176.7 73.1
435
439
434
420
243
279
405
394
249
MEAN 131.7 186.0 149.0 137.6 135.3
SE 10.8 15.8 12.6 8.5 10.3
Urinary Sodium (Na), mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
IGS2 1GS2 IGS2 IGS2 IGS2
C I BR 1 BR2 BR3 BR4
117.4 198.0 208.8 157.7 136.4
I41.8 I88.1 202.7 126.5 126.0
195.2 159.1 233.4 211.8 106.6
184.1 184.5 117.7 149.0 121.8
98.4 164.3 195.4 186.6 83.4
182.0 233.1 138.3 169.0 162.2
258.0 189.0 232.6 132.4 112.2
212.3 281.1 232.9 202.1 i 08.9
MEAN 173.6 199.7 195.2 166.9 119.7
SE 18.5 14.1 15.7 11.1 8.2
1GS4, 1GW4, and 1GS2 denote respectively the 4 hr stand, 4 hr walk, and 2 hr stand treatment
conditions. CI, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Urinary Sodium (Na), mEq/24 hr
1GW2 1GW2
Subject No.
435
439
434
420
243
279
405
394
249i
MEAN
SE
1GW2 1GW2 1GW2
C 1 BR 1 BR2 BR3 BR4
122.9 183.3 188.6 111.8 149.0
191.2 215.1 148.2 133.7 129.0
159.4 169.6 155.1 140.7 114.7
109.1 129.3 167.9 128.1 146.1
240.6 179.3 167.6 142.1 87.6
202.2 215.5 157.1 166. I 137.3
244.3 157.4 184.0 160.5 89.8
196.0 222.7 141.1 150.7 139.5
183.2 184.0 163.7 141.7 124.1
17.6 11.5 5.9 6.2 8.6
Sodium (Na) Balance, mEq/24 hr, determined from Urinary Sodium (Na) minus Sodium (Na)
Intake
Subject No.
435
439
434
420i
243
279
405
394
249
0G 0G 0G
C1 BR1 BR2
17.8 -10.6 -57.3
104.4 22.5 33.4
22.1 12.3 8.8
10.4 18.9 3.5
0G 0G
BR3 BR4
22.3 45.6
59.2 78.9
32.2 72.9
42.7 55.7
50.5 77.9
1.5 34.7
40.0 16.1
61.6 52.8
-2.8 85.5
10.6 -35.3 28.6
-15.3 -23.7 18.7
-80.1 -10.8 -20.3
32.8 -98.7 9.5
-13.9 -36.2 3.2
MEAN 9.9 -18.0 3.1 34.1 57.8
SE 16.2 12.5 9.2 7.8 7.7
i
0G and 1GW2 denote respectively the no treatment condition and the 2 hr walk treatment condition.
CI, BR1, BR2, BR3, and BR4 denote ambulatory cona'ol and HDBR days.
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Sodium (Na) Balance, mEq/24 hr, determined from Urinary Sodium (Na) minus Sodium (Na)
Intake
Subject No.
435
439
434
420
243
279
405
394
249
IGS4 IGS4 IGS4 1GS4 IGS4
C1 BR1 BR2 BR3 BR4
8.6 -21.2 - 15.1 24.7 31.5
70.7 37.5 27.6 -5.1 -17.5
0.8 27.8 18.1 11.9 41.6
81.9 67.6 42.7 -6.3 25.0
82.5 40.8 25.5 12.0 46.1
110.9 33.8 28.0 9.3 21.5
70.5 8.0 19.5 6.0 4.1
25.7 -30.9 25.4 15.1 40.1
-6.1 -77.5 32.5 41.0 51.5
MEAN 49.5 9.5 22.7 12.1 27.1
SE 14.2 15.0 5.3 4.8 7.4
Sodium (Na) Balance, mEq/24 hr, determined from Urinary Sodium (Na) minus Sodium (Na)
Intake
1GW4 1GW4
Subject No.
435
439
434
420 I
243!
279 i
405 I
394
249
1GW4 1GW4 1GW4
C1 BRI BR2 BR3 BR4
50.5 -79.8 14.5 10.5 21.3
51.8 -3.2 0.1 44.0 23.2
0.7 55.5 25.3 72.3 30.3
78.2 65.8 48.0 12.4 68.0
38.7 - 18.6 21.4 54.4 60.6
23. I 66.9 5.5 38.5 31.8
25.8 -17.5 35.1 44.3 18.0
77.8 -10.3 66.9 63.5 30.5
-11.5 -32.2 117.5 -8.1 115.6
MEAN 37.2 3.0 37.1 36.9 44.4
SE 10.4 16.7 12.2 8.9 10.6
1GS4 and 1GW4 denote respectively the 4 hr stand and 4 hr walk treatment conditions. CI, BRI,
BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Sodium (Na) Balance, mEq124 hr, determined from Urinary Sodium (Na) minus Sodium (Na)
Intake
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2 IGS2 1GS2 1GS2
C 1 BR 1 BR2 BR3 BR4
44.5 - 1.6 -42.9 28.2 31.3
20.1 11.6 -39.9 59.4 40.9
-90.3 -8.6 -5.6 -49.2 68.9
-12.2 -18.9 53.5 17.3 24.4
53.2 34.9 4.0 -35.3 92.3
1.4 -67.2 47.7 11.7 -10.1
- 106.8 7.1 -29.6 30.2 35.8
-29.5 - 118.5 -47.5 -31.8 42.7
MEAN - 15.0 -20.2 -7.5 3.8 40.8
SE 20.7 17.5 14.2 13.5 10.7
Sodium (Na) Balance, mEq/24 hr, determined from Urinary Sodium (Na) minus Sodium (Na)
Intake
Subject No.
435
439i
434
420
2431
279!
4051
394
249
1GW2 1GW2 1GW2 1GW2 1GW2
C 1 BR 1 BR2 BR3 BR4
82.7 16.7 -22.7 74.1 18.7
14.4 - 15.6 17.7 52.3 37.9
42.9 29.5 - 1.8 44.5 51.1
52.6 54.4 -2.3 43.0 16.5
-97.3 -21.8 31.8 23.5 88.1
-50.0 -16.0 42.6 -3.3 38.6
- 101.4 -9.0 - 16.0 2.1 77.7
-13.2 -69.4 17.3 29.7 12.1
_dEAN -8.7 -3.9 8.3 33.2 42.6
SE 24.5 13.3 8.1 9.1 10.0
1GS2 and 1GW2 denote respectively the 2 hr stand and 2 hr walk treatment conditions. C1,
BR2, BR3, and BR4 denote ambulatory control and HDBR days.
BR1,
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Potassium (K) Intake,' mEq/24 hr
Subject No.
0(3 0G 0(3 0G 0G
C 1 BR 1 BR2 BR3 BR4
92.2 86.0 85.8 83.4 90.8
92.0 84.4 83.9 81.8 90.6
92.0 85.8 82.6 66.1 86.1
75.1 79.9 87.3 78.1 87.7
89.0 83.7 87.3 79.7 88.6
83.8 57.4 81.5 64.1 84.0
92.3 89.6 84.9 85.5 93.0
87.3 86.1 81.3 83.8 91.7
90.1 87.6 83.7 84.9 94.2
435
439
434
42(
243
279
405
394
249
MEAN 88.2 82.3 84.3 78.6 89.6
SE 1.9 3.2 0.8 2.7 1.I
Potassium (K) Intake, m.Eq/24 hr
IGS4
Subject No. CI
435 95.2
439 93.4
434 96.1
420 88.6
243 97.3
279 92.9
405 94.8
394 97.4
249 91.7
1GS4 IGS4 1GS4 1GS4
BRI BR2 BR3 BR4
89.6 83.4 88.3 100.9
84.0 85.7 91.7 99.1
84.8 86.1 80.9 74.6
81.9 82.4 88.8 97.2
87.6 83.7 83.5 90.3
83.9 71.4 85.5 94.6
84.4 81.5 85.3 99.5
83.5 81.0 84.7 82.9
86.1 81.4 86.3 98.9
MEAN 94.2 85.1- 81.8 86.1 93.1
SE 0.9 0.8 1.4 1.1 3.0
Potassium (K) Intake, mEq/24 hr
Subject NO.
IMEAN
SE
1GW4 1GW4 1GW4 1GW4 1GW4
C1 BR 1 BR2 BR3 BR4
100.9 88.3 89.6 85.8 92.6
93.4 89.6 81.8 86.4 99.2
99.0 86.2 76.8 86.1 78.2
97.3 86.3 80.1 82.9 89.1
93.0 82.1 84.7 89.8 97.3
95.7 84.5 83.8 80.7 84.5
99.1 88.3 86.0 88.1 91.2
89.4 82.4 80.4 84.9 96.5
97.5 87.7 84.0 82.4 90.6
435
439
434
420
243
279
405
394
249
96.1 86.2 83.0 85.2 91.0
1.2 0.9 1.2 1.0 2.2
0(3, 1GS4, and 1GW4 denote respectively the no treatment condition and the 4 hr stand and 4 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Potassium (K) Intake, mEq/24 hr
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
1GS2
CI
99.2
99.3
81.5
86.6
98.7
90.6
96.4
88.0
92.5
2.4
1GS2
BR1
88.5
87.5
102.9
82.2
104.9
1GS2
BR2
83.5
83.6
96.3
81.8
87.1
1GS2
BR3
89.5
90.5
82.2
87.4
81.0
83.5
97.6
82.2
89.1
87.2
87.5
89.5
82.2
83.2
91.2
3.3
87.0
1.6
85.7
1.4
1GS2
BR4
93.8
89.0
92.9
96.5
93.0
101.1
83.1
98.8
93.5
2.0
Potassium (K) Intake, m Eq/24 hr
Subject No,
435
439
434
420
243
279
405
394
249
1GW2 1GW2 1GW2 IGW2 1GW2
C 1 BR 1 BR2 BR3 BR4
101.1 89.4 83.5 89.5 93.8
101.2 112.8 83.6 89.2 89.1
99.7 86.0 81.3 87.3 85.6
97.6 83.3 82.2 82.2 80.4
98.7 102.7 87.1 81.9 93.0
99.5 106.5 87.8 83.8 93.6
97.5 102.9 83.4 82.0 89.0
89.9 81.3 80.3 89.3 98.8
MEAN 98.2 95.6 83.7 85.7 90.4
SE 1.3 4.2 0.9 1.2 2.0
Urinary Potassium (K), mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G 0G
C 1 BR 1 BR2 BR3 BR4
70.2 54.1 66.5 58.2 63.2
39.5 35.0 46.6 68.8 75.4
59.0 51.3 63.8 91.8 67.9
59.9 59.6 59.7 63.0 57.5
85.4 70.2 70.3 72.4 75.0
78.1 59.8 55.3 67.5 50.0
79.5 55.5 69.0 70.1 70.8
30.0 48.8 56.2 66.4 63.8
67.8 45.5 36.8 73.0 65.1
MEAN 63.3 53.3 58,2 70.1 65.4
SE 6.2 3.3 3.7 3.1 2.7
0(3, IGS2, and IGW2 denote respectively the no treatment condition and the 2 hr stand and 2 hr walk
treatment conditions. CI, BR1, BR2, BR3, and BR4 and denote ambulatory control and HDBR days.
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Urinary Potassium (K), mEq/24 hr
Subject No.
1GS4 1GS4 1GS4 1GS4 1GS4
C 1 BR 1 BR2 BR3 BR4
82.8 66.4 70.0 71.5 59.7
91.0 78.2 71.0 74.6 69.6
48.7 98.4 79.0 86.0 90.1
61.2 51.8 58.0 67.3 59.2
66.2 70.6 74.7 86.2 65.5
51.3 75.2 61.2 65.0 73.4
62.9 67.0 79.3 77.8 69.4
31.8 51.3 59.2 68.3 81.1
53.1 51.5 59.2 61.2 74.9
435
439
434
420
243
279
405
394
249
MEAN 61.0 67.8 68.0 73.1 71.4
SE 6.0 5.1 2.9 3.0 3.3
Urinary Potassium (K), mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW4 1GW4 1GW4 1GW4 1GW4
C 1 BR 1 BR2 BR3 BR4
67.3 102.8 73.2 65.4 65.2
64.3 77.5 93.0 70.1 62.1
56.5 84.9 77.9 61.8 89.6
60.6 105.0 63.8 93.2 65.5
69.1 78.1 78.7 69.6 77.2
42.7 69.1 65.7 57.3 74.2
78.0 118.8 66.4 65.4 82.9
47.5 64.6 80.1 79.3 84.7
47.8 87.0 38.9 130.3 66.6
MEAN 59.3 87.5 70.9 76.9 74.2
SE 3.9 6.0 5.0 7.5 3.3
Urinary.Potassium (K), mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 IGS2 1GS2 1GS2 IGS2
C 1 BR 1 BR2 BR3 BR4
82.3 69.1 69.2 67.9 57.2
62.6 62.7 71.7 47.2 56.5
70.8 59.4 82.5 77.0 68.6
84.4 55.4 51.3 65.9 61.5
55.7 74.8 80.5 61.2 59.6
63.7 62.8 50.1 86.9 77.9
56.3 44.8 50.6 43.5 63.9
67.1 43.4 43.0 72.3 84.0
MEAN 67.9 59.1 62.4 65.2 66.2
SE 3.8 3.9 5.4 5.1 3.5
1GS4, 1GW4, and 1GS2 denote respectively the 4 hr stand, 4 hr walk, and 2 hr stand treatment
conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Urinary Potassium (K), mEq/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 1GW2 1GW2 1GW2 1GW2
CI BRI BR2 BR3 BR4
84.0 58.0 70.6 67.0 66.2
77.4 99.3 69.8 83.6 75.7
66.7 92.5 73.8 71.5 71.4
73.1 83.6 76.5 64.9 68.7
71.4 74.9 63.5 61.2 60.5
93.4 95.5 93.6 69.2 64.8
56.6 51.3 62.5 70.0 69.1
68.7 53.0 58.1 65.9 69.3
MEAN 73.9 76.0 71.0 69.2 68.2
SE 4.0 7.0 3.9 2.4 1.6
Potassium (K) Balance, mEq/24 hr, determined from Urinary Potassium (K) minus
Potassium (K) Intake
0G
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G
C 1 BR 1 BR2 BR3 BR4
22.0 31.9 19.3 25.2 27.6
52.5 49.4 37.3 13.0 15.2
33.0 34.5 18.8 -25.7 18.2
15.2 20.3 27.6 15.1 30.2
3.6 13.5 17.0 7.3 13.6
5.7 -2.4 26.2 -3.4 34.0
12.8 34.1 15.9 15.4 22.2
57.3 37.3 25.1 17.4 27.9
22,3 42.1 46.9 11.9 29.1
MEAN 24.9 29.0 26.0 8.5 24.2
SE 6.4 5.3 3.4 5.0 2.4
0G and 1GW2 denote respectively the no treatment condition and the 2 hr walk treatment condition.
C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Potassium (K) Balance, mEq/24 hr, determined from Urinary Potassium (K) minus
Potassium.(.K) Intake ..
Subject No.
435
439
434
420
243
279
405
394
249
1GS4 IGS4 1GS4 IGS4 IGS4
C 1 BR 1 BR2 BR3 BR4
12.4 23.2 13.4 16.8 41.2
2.4 5.8 14.7 17.1 29.5
47.4 -13.6 7.1 -5.1 -15.5
27.4 30.1 24.4 21,5 38.0
31.1 17.0 9.0 -2.7 24.8
41.6 8.7 10.2 20.5 21.2
31.9 17.4 2.2 7.5 30.1
65.6 32.2 21.8 16.4 1.8
38.6 34.6 22.2 25,1 24.0
MEAN 33.2 17.3 13.9 13.0 21.7
SE 6.2 5.1 2.5 3.6 6.0
Potassium (K) Balance, mEq/24 hr, determined from Urinary Potassium (K) minus
Potassium (K) Intake
Subject No.
435
439
434
420
243
279
405
394
249
1GW4 1GW4 1GW4 1GW4 1GW4
C 1 BR1 BR2 BR3 BR4
33.6 - 14.5 16.4 20.4 27.4
29.1 12.1 -11.2 16.3 37.1
42.5 1.3 -1.1 24.3 -11,4
36.7 - 18.7 16.3 - 10.3 23.6
23,9 4,0 6,0 20,2 20,1
53.0 15.4 18.1 23.4 10.3
21.1 -30.5 19.6 22.7 8.3
41.9 17.8 0.3 5.6 11.8
49.7 0.7 45.1 -47.9 24.0
MEAN 36.8 -1.4 12.2 8.3 16.8
SE 3.7 5.5 5.4 8.0 4.7
1GS4 and 1GW4 denote respectively the 4 hr stand and 4 hr walk treatment conditions. CI, BRI, BR2,
BR3, and BR4 denote ambulatory control and HDBR days.
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Potassium (K) Balance, mEqt24 hr, determined from Urinary Potassium (K) minus
Potassium (K) Intake
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 IGS2 1GS2 1GS2 1GS2
C1 BRI BR2 BR3 BR4
16.9 19.4 14.3 21.6 36.6
36.7 24.8 11.9 43.3 32.5
10.7 43.5 13.8 5.2 24.3
2.2 26.8 30.5 21.5 35.0
43.0 30.1 6.6 19.8 33.4
26.9 20.7 39.0 2.6 23.2
40.1 52.8 36.6 38.7 19.2
20.9 38.8 44.5 10.9 14.8
MEAN 24.7 32.1 24.7 20.5 27.4
SE 5.2 4.2 5.2 5.2 2.9
Potassium (K) Balance, mEq124 hr, determined from Urinary Potassium (K) minus
Potassium (K) Intake
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 1GW2 1GW2 1GW2 1GW2
C1 BRI BR2 BR3 BR4
17.1 31.4 12.9 22.5 27.6
23.8 13.5 13.8 5.6 13.4
33.0 -6.5 7.5 15.8 14.2
24.5 -0.3 5.7 17.3 11.7
27.3 27.8 23.6 20.7 32.5
6.1 11.0 -5.8 14.6 28.8
40.9 51.6 20.9 12.0 19.9
21.2 28.3 22.2 23.4 29.5
MEAN 24.2 19.6 12.6 16.5 22.2
SE 3.7 6.7 3.5 2.1 3.0
IGS2 and 1GW2 denote respectively the 2 hr stand and 2 hr walk treatment conditions. C1, BRI,
BR3, and BR4 denote ambulatory conlrol and HDBR days.
BR2,
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Daily Fluid Intake, ml/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G 0G
C1 BR1 BR2 BR3 BR4
2120 2060 2260 2130 1990
3503 2814 2814 2569 2244
2090 1835 1585 1160 990
1265 1130 1445 1130 1250
1405 1460 1920 1780 1900
1983 1781 1428 1528 1519
1985 1890 2080 1690 2115
1503 1454 1224 1368 1014
1475 1770 1720 1610 1610
MEAN 1925 1799 1831 1663 1626
SE 225 158 166 154 156
DailyFluid lntake, mg24 hr .
435
439
434
420
243
279
405
394
249
Subject No.
1GS4 1GS4 1GS4 1GS4 IGS4
CI BR1 BR2 BR3 BR4
2150 2100 1950 2135 1890
1428 1524 1374 1773 1734
1460 1080 1395 1110 1140
890 1575 1400 1415 1250
2235 2200 1945 2250 2140
1705 1935 1575 2074 1445
1995 2000 1935 2075 2315
1029 1080 1300 1230 1035
1369 1625 2300 1775 1730
iMEAN 1585 1680 1686 1760 1631
SE 158 138 118 140 149
IDaily Fluid Intake, ml/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW4 1GW4 1GW4 IGW4 1GW4
C1 BR1 BR2 BR3 BR4
2360 2250 1970 2320 1930
1668 1818 1808 1813 1654
1035 1924 1234 1804 1215
1519 1909 1990 1920 1550
1430 2195 1980 2235 1465
2288 2621 2439 2930 1605
1990 2070 1890 2065 1650
1585 1565 1860 1640 1315
1825 1930 2075 2399 1845
MEAN 1744 2031 1916 2125 1581
SE 141 100 105 132 76
0G, 1GS4, and IGW4 denote respectively the no treatment condition and the 4 hr stand and 4 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Daily Fluid Intake, ml/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
IVlEAN
SE
IGS2
CI
1880
1338
1504
1330
2375
1945
1299
1685
1670
134
IGS2
BRI
2430
1494
1045
1699
2055
1GS2
BR2
2060
1344
2035
1254
2320
IGS2
BR3
2170
1848
1345
1135
1740
2000
1089
1345
1990
1968
1610
2000
1504
1760
1645
174
1823
133
1688
121
1GS2
BR4
2070
1134
1190
1375
1460
2085
770
1505
1449
160
Daily Fluid Intake, ml/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 1GW2 1GW2 1GW2 1GW2
CI BR1 BR2 BR3 BR4
2340 2570 2120 2230 1990
1338 1730 1879 1729 1434
1155 1615 1920 1840 780
920 1615 1700 1255 1135
1905 1570 2460 2420 1710
2000 2000 2000 2000 2000
1689 1344 1614 1104 1404
1785 1700 1730 1775 1605
MEAN 1642 1768 1928 1794 1507
SE 167 132 96 158 147
!Daily Fluid (Urinary)Output, mV24 hr
Subject No.
435
439
434
420
243
279
405
394
249
SE
0G 0G 0G 0G 0G
CI BR1 BR2 BR3 BR4
1839 1852 2058 1855 1361
2182 2084 1042 1316 1080
2963 1726 1150 1180 1180
1429 968 1002 892 1115
1375 1595 1620 1340 1460
1915 1875 1257 1247 1440
2790 1838 2205 1670 2233
1080 1676 1045 928 895
1675 1598 1140 1640 794
1916 1690 1391 1341 1284
212 104 153 110 141
0G, IGS2, and 1GW2 denote respectively the no treatment condition and the 2 hr stand and 2 hr walk
treatment conditions. CI, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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Daily Fluid (Urinary) Output, mi/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GS4 1GS4 IGS4 IGS4 IGS4
C1 _ BR1 BR2 BR3 BR4
2197 1977 1983 1633 1505
1333 1222 1183 1275 1324
1827 1060 1140 1047 1110
765 863 954 1182 1020
1840 2035 2024 1793 1820
1420 1548 1633 2124 1366
1650 1642 1915 1848 2030
1007 1111 1007 1065 1008
1670 1480 1960 1275 1191
MEAN 1523 1438 1533 1471 1375
SE 148 136 152 129 119
Daily Fluid (Urinary) Output, ml/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW4 1GW4 1GW4 1GW4 1GW4
C1 BR1 BR2 BR3 BR4
2435 1525 1112 1307 1534
1635 1307 1208 1054 1040
1490 1065 975 685 1052
1250 1207 905 1051 835
1650 1750 1460 1520 1020
2465 1259 1500 1842 1040
2487 1630 1061 1051 1598
773 1006 986 946 1115
2025 1485 540 1575 687
!MEAN 1801 1359 1083 1226 1102
SE 200 85 97 121 98
Daily Fluid (Urinary)Output, mU24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 IGS2 1GS2 1GS2 1GS2
C1 BR1 BR2 BR3 BR4
2048 2195 2330 1821 2020
1385 1465 1347 1204 1158
2046 1530 2365 1762 1502
1233 2014 989 1400 1395
2200 2580 1988 2090 833
2449 2642 1672 2110 2195
1180 1470 1592 1483 1014
1398 2282 1402 2090 1205
MEAN 1742 2022 1711 1745 1415
SE 175 172 172 124 169
1GS4, 1GW4, and 1GS2 denote respectively the 4 hr stand, 4 hr walk, and 2 hr stand treatment
conditions. C1, BRI, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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100
Daily Fluid (Urinary) Output, mi/24 hr
Subject No.
435
439
434
420
243
279
405
394
249
1GW2 1GW2 IGW2 1GW2 1GW2
C1 BR1 BR2 BR3 BR4
2780 1840 2057 1203 1891
2015 1412 1063 1125 1051
1765 1121 1519 1521 898
1290 1005 1465 1012 995
2635 2080 1615 2060 952
2512 2745 1262 2036 1779
1465 1180 1275 1057 878
1710 1865 1109 1265 1260
MEAN 2022 1656 1421 1410 1213
SE 198 209 114 150 142
DailyFluid Balance, mi/24 hr,determined from Fluid Out minus Fluid In
Subject No.
435
439
434
420
243
279
405
394
249
0G 0G 0G 0G 0G
CI BR1 BR2 BR3 BR4
281 208 202 275 629
1321 730 1772 1253 1164
-873 109 435 -20 -190
-164 162 443 238 135
30 -135 300 440 440
68 -94 171 281 79
-805 52 -125 20 -118
423 -222 179 440 119
-200 172 580 -30 816
MEAN 9 109 440 322 342
SE 220 92 180 131 151
Daily FluidBalance, mi/24 hr, determined from Fluid Out minus Fluid In
IGS4 IGS4 IGS4
Subject No.
435
439
434
420
243
279
405
394
249
1GS4 1GS4
C1 BR1 BR2 BR3 BR4
-47 123 -33 502 385
95 302 191 498 410
-367 20 255 63 30
125 712 446 233 230
395 165 -79 457 320
285 387 -58 -50 79
345 358 20 227 285
22 -31 293 165 27
-301 145 340 500 539
MEAN 61 242 153 288 256
SE 89 76 65 70 60
0(3, 1GS4, and 1GW2 denote respectively the no treatment condition and the 4 hr stand and 2 hr walk
treatment conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
Daily Fluid Balance, ml]24 hr, determined from Fluid
Subject No.
Out minus Fluid In
435
439
434
420i
243
2791
405
394
249
IGW4 1GW4 1GW4 IGW4 1GW4
CI BR1 BR2 BR3 BR4
-75 725 858 1013 396
33 511 600 759 614
-455 859 259 1119 163
269 702 1085 869 715
-220 445 520 715 445
-177 1362 939 1088 565
-497 440 829 1014 52
812 559 874 694 200
-200 445 1535 824 1158
MEAN -57 672 833 899 479
SE 134 99 121 54 112
Daily Fluid Balance, mF24hr, determined fromFluid Out minus Fluid In
Subject No.
435
439
434
420
243
279
405
394
249
1GS2 1GS2 1GS2 IGS2 IGS2
C 1 BR 1 BR2 BR3 BR4
-168 235 -270 349 50
-47 29 -3 644 -24
-542 -485 -330 -4 17 -312
-97 -315 265 -265 -20
175 -525 332 -350 627
-504 -642 318 -110 -110
-119 -381 376 21 -244
-287 -937 208 -330 300
MEAN -199 -378 112 -57 33
SE 84 131 99 134 107
Daily Fluid Balance, mF24hr, determined from FluidOutminus Fluid In
Subject No.
MEAN
SE
435
439
434
420
243
279
405
394
249
IGW2 1GW2 1GW2 IGW2 IGW2
CI BRI BR2 BR3 BR4
-440 730 63 1027 99
-677 318 816 604 383
-610 494 401 319 -118
-370 610 235 243 140
-730 -510 845 360 758
-512 -745 738 -36 221
224 164 339 47 526
75 -165 621 510 345
-380 112 507 384 294
124 190 102 119 96
1GW4, 1GS2 and 1GW2 denote respectively the 4 hr walk, 2 hr stand, and 2 hr walk treatment
conditions. C1, BR1, BR2, BR3, and BR4 denote ambulatory control and HDBR days.
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